{"gene":"BCAT1","run_date":"2026-04-28T17:12:38","timeline":{"discoveries":[{"year":2013,"finding":"BCAT1 initiates BCAA catabolism in glioblastoma cells; suppression of BCAT1 blocked glutamate excretion, reduced proliferation and invasiveness in vitro, and decreased tumor growth in xenograft models, establishing BCAT1 as required for glioma cell proliferation through amino acid catabolism.","method":"shRNA knockdown in glioma cell lines + xenograft model; metabolite measurements (glutamate excretion); ectopic mutant IDH1 overexpression suppressing BCAT1","journal":"Nature medicine","confidence":"High","confidence_rationale":"Tier 2 — clean KD with defined metabolic and cellular phenotype, replicated in vivo, multiple orthogonal methods","pmids":["23793099"],"is_preprint":false},{"year":2013,"finding":"c-Myc directly binds the BCAT1 promoter and transcriptionally upregulates BCAT1 expression in nasopharyngeal carcinoma cells, as demonstrated by ChIP and luciferase reporter assays.","method":"ChIP assay; luciferase reporter assay; c-Myc siRNA knockdown reducing BCAT1 expression","journal":"Molecular cancer","confidence":"High","confidence_rationale":"Tier 1/2 — ChIP + luciferase reporter + siRNA knockdown, multiple orthogonal methods in single study","pmids":["23758864"],"is_preprint":false},{"year":2017,"finding":"BCAT1 transfers α-amino groups from BCAAs to α-ketoglutarate (αKG), thereby restricting intracellular αKG levels in AML stem cells; BCAT1 knockdown caused αKG accumulation leading to EGLN1-mediated HIF1α degradation; BCAT1 overexpression decreased αKG and caused TET2-dependent DNA hypermethylation, mimicking IDH mutation effects.","method":"BCAT1 knockdown/overexpression in AML cells; metabolomics (intracellular αKG measurement); proteomic analysis; DNA methylation profiling; HIF1α protein level measurement","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1-2 — multiple orthogonal methods (metabolomics, proteomics, epigenomics), gain- and loss-of-function, strong mechanistic chain established","pmids":["29144447"],"is_preprint":false},{"year":2014,"finding":"BCATc (BCAT1) expression is induced by T cell receptor (TCR) signaling via the calcineurin-NFAT pathway in CD4+ T cells; BCATc controls intracellular leucine levels, and its absence increases mTORC1 activation (elevated S6 and 4EBP-1 phosphorylation) and glycolytic metabolism.","method":"BCATc knockout mouse; cyclosporin A (calcineurin-NFAT inhibitor) treatment; leucine transamination assay; mTORC1 substrate phosphorylation (immunoblot); glycolysis measurement (Seahorse)","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 — genetic KO model + pharmacological inhibition + biochemical assays, multiple orthogonal methods","pmids":["24847056"],"is_preprint":false},{"year":2004,"finding":"BCATc (BCAT1) is exclusively expressed in neurons (not astrocytes) in the adult rat brain; in glutamatergic neurons it localizes to axons and nerve terminals, while in GABAergic neurons it concentrates in cell bodies, suggesting a role in regulating glutamate available for neurotransmitter release or GABA synthesis.","method":"Immunohistochemistry in rat brain; cell-type-specific localization in cerebellum and hippocampus","journal":"The Journal of comparative neurology","confidence":"Medium","confidence_rationale":"Tier 3 — direct localization by IHC with functional interpretation, single study","pmids":["15329886"],"is_preprint":false},{"year":1999,"finding":"Overexpression of BCAT1/ECA39 in murine cells promotes apoptosis under serum deprivation; the branched-chain keto acid α-ketoisocaproate (product of leucine catabolism by BCAT1) can independently induce rapid apoptotic cell death, suggesting the apoptotic effect is mediated by BCAA-derived keto acid metabolites.","method":"Overexpression of BCAT1 in murine cells; serum deprivation assay; α-ketoisocaproate treatment; cell viability/apoptosis assays","journal":"FEBS letters","confidence":"Medium","confidence_rationale":"Tier 2 — gain-of-function + metabolite supplementation with defined phenotypic readout (apoptosis), single lab","pmids":["10471790"],"is_preprint":false},{"year":2017,"finding":"BCAT1 promotes breast cancer cell growth by activating mTOR signaling, enhancing mitochondrial biogenesis and ATP production, and suppressing mitochondrial ROS; this effect is specific to mTOR (not AMPK or SIRT1).","method":"BCAT1 knockdown/overexpression in breast cancer cells; mTOR pathway inhibitor; colony formation; mitochondrial biogenesis and ATP production assays","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 3 — KD/OE with pathway inhibitor rescue, single lab","pmids":["28235484"],"is_preprint":false},{"year":2020,"finding":"In pancreatic ductal adenocarcinoma, TGF-β signaling via the SMAD5 axis directly targets BCAT1 in cancer-associated fibroblasts (CAFs), dictating internalization of extracellular matrix to supply amino acid precursors for branched-chain α-ketoacid (BCKA) secretion by CAFs that fuels PDAC cancer cells.","method":"TGF-β/SMAD5 pathway manipulation in CAFs; isotope tracing of BCAA metabolism; BCAT1 knockdown in CAFs; CTC and PDAC tissue slice validation","journal":"Nature metabolism","confidence":"High","confidence_rationale":"Tier 1-2 — pathway epistasis (TGF-β-SMAD5-BCAT1), isotope tracing, multiple model systems including patient-derived material","pmids":["32694827"],"is_preprint":false},{"year":2022,"finding":"BCAT1 localizes to mitotic structures and has a non-metabolic moonlighting function as a mitotic regulator; its CXXC redox motif controls cysteine sulfenylation in mitotic cells, promoting Aurora kinase B localization to centromeres and securing accurate chromosome segregation.","method":"Gene knockout and rescue strategies in cancer cells and iPSCs; live cell imaging of BCAT1 at mitotic structures; CXXC motif mutagenesis; Aurora B localization by immunofluorescence; chromosome segregation assays; cerebral organoid and mouse syngraft tumor growth models","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 1-2 — reconstitution of function by rescue with wild-type vs. CXXC mutant, multiple orthogonal assays, in vivo validation","pmids":["36260995"],"is_preprint":false},{"year":2022,"finding":"The BCAT1 CXXC motif has antioxidant activity: purified wild-type BCAT1 protein can metabolize H2O2 in vitro, whereas CXXC motif mutant BCAT1 or wild-type BCAT2 cannot; this activity buffers intracellular ROS in AML cells and reduces myeloid differentiation markers.","method":"In vitro H2O2 metabolism assay with purified recombinant BCAT1 wild-type vs. CXXS mutant; intracellular ROS measurement in U937 AML cells overexpressing WT vs. CXXS BCAT1; myeloid differentiation markers (CD11b, CD14, CD68, CD36)","journal":"Antioxidants (Basel, Switzerland)","confidence":"High","confidence_rationale":"Tier 1 — in vitro reconstitution with purified protein + mutagenesis + cellular validation","pmids":["35453368"],"is_preprint":false},{"year":2022,"finding":"Loss of BCAT1 in IDH-wildtype GBM cells increases NAD+/NADH ratio but impairs oxidative phosphorylation, mTORC1 activity, and nucleotide biosynthesis; supplementation with branched-chain α-ketoacids (BCKA, downstream products of BCAT1) rescues these defects and prevents cell death, establishing BCAT1-generated BCKAs as the critical downstream mediators.","method":"BCAT1 inhibitor (gabapentin) + αKG co-treatment synthetic lethality screen; BCAT1 KO + BCKA supplementation rescue; patient-derived GBM in vitro and in vivo models; metabolic measurements (NAD+/NADH, nucleotides, ATP, mTORC1 substrates)","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 1-2 — metabolic synthetic lethal screen + KO + metabolite rescue + in vivo validation, multiple orthogonal methods","pmids":["35499760"],"is_preprint":false},{"year":2023,"finding":"BCAT1 directly interacts with RhoC GTPase, elevating RhoC activity; additionally, BCAA-derived branched-chain α-keto acids (BCKAs) directly bind to RhoC and promote its GTPase activity, linking BCAT1 enzymatic activity to cell motility through RhoC activation.","method":"Co-immunoprecipitation of BCAT1-RhoC interaction; BCKA direct binding to RhoC (biochemical binding assay); BCAT1 gain-of-function mutation (E61A) with higher enzymatic activity; BCAT1 KO rescue with BCAT1-E61A or BCKA supplementation; in vivo peritoneal metastasis model; candesartan identified as BCAT1-E61A inhibitor","journal":"Nature metabolism","confidence":"High","confidence_rationale":"Tier 1-2 — direct protein interaction (Co-IP), direct metabolite-protein binding, gain-of-function mutagenesis, rescue experiments, in vivo validation","pmids":["37337119"],"is_preprint":false},{"year":2021,"finding":"BCAT1 increases cisplatin resistance in cancer cells by inducing mTOR-mediated autophagy via leucine metabolism; cisplatin upregulates BCAT1, which decreases leucine availability to suppress mTOR signaling and activate autophagy, thereby reducing cisplatin sensitivity.","method":"BCAT1 knockdown/overexpression; leucine and BCAA supplementation rescuing mTOR activity and autophagy; chloroquine (autophagy inhibitor) in vivo; mTOR substrate phosphorylation assays","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 — KD/OE + metabolite rescue + in vivo, single lab with multiple methods","pmids":["33568627"],"is_preprint":false},{"year":2022,"finding":"BCAT1 promotes osteoclast maturation through its enzymatic BCAA catabolism activity; enzymatically dead BCAT1 abrogated osteoclast maturation, and the specific BCAT1 inhibitor gabapentin reduced osteoclast differentiation and inhibited LPS-induced bone loss in mice.","method":"Expression of enzymatically dead BCAT1 mutant; gabapentin (BCAT1 inhibitor) treatment; in vitro RANKL-induced osteoclast differentiation assay; in vivo LPS-induced calvaria bone loss model","journal":"Experimental & molecular medicine","confidence":"High","confidence_rationale":"Tier 1-2 — catalytic dead mutant + pharmacological inhibition + in vivo model; enzymatic activity specifically required","pmids":["35760874"],"is_preprint":false},{"year":2024,"finding":"BCKDK phosphorylates BCAT1 at S5, S9, and T312, increasing its catalytic and antioxidant activity and stability; STUB1 is an E3 ubiquitin ligase for BCAT1 that promotes K48-linked ubiquitin degradation of BCAT1; BCKDK phosphorylation of STUB1 at S19 disrupts its interaction with BCAT1, thereby inhibiting BCAT1 ubiquitination and degradation.","method":"Mass spectrometry identification of phosphorylation sites; co-immunoprecipitation of BCKDK-BCAT1 and STUB1-BCAT1; mutagenesis of phosphorylation sites; ubiquitination assay; in vitro kinase assay; in vivo xenograft model","journal":"Cancer letters","confidence":"High","confidence_rationale":"Tier 1-2 — phosphorylation site mapping by MS + mutagenesis + Co-IP + ubiquitination assay, multiple orthogonal methods","pmids":["38621458"],"is_preprint":false},{"year":2024,"finding":"CHIP (STUB1) E3 ubiquitin ligase interacts with BCAT1 via its coiled-coil domain, promoting K48-linked ubiquitination and proteasomal degradation of BCAT1 at K360; reduced CHIP expression leads to high BCAT1 in glioma cells, and CHIP-mediated BCAT1 degradation reduces glutathione synthesis, increases oxidative stress, and sensitizes glioma cells to temozolomide.","method":"Co-immunoprecipitation of CHIP-BCAT1; domain mapping (CC domain); ubiquitination site mutagenesis (K360); proteasome inhibitor treatment; GSH measurement; in vitro and in vivo glioma models","journal":"Cell death & disease","confidence":"High","confidence_rationale":"Tier 1-2 — Co-IP + domain mapping + site mutagenesis + functional rescue, multiple orthogonal methods","pmids":["39075053"],"is_preprint":false},{"year":2025,"finding":"SIRT5 desuccinylates BCAT1 at K39, preventing its interaction with the E3 ligase CHIP and thereby stabilizing BCAT1 protein against ubiquitin-proteasome degradation, leading to increased BCAA catabolism, ferroptosis resistance, and glioma cell proliferation.","method":"Proteomics/metabolomics identifying BCAT1 as SIRT5 substrate; succinylation site mapping at K39; co-immunoprecipitation of BCAT1-CHIP interaction; SIRT5 knockdown + BCAT1 overexpression rescue; in vitro and in vivo glioma models","journal":"Cell death & disease","confidence":"High","confidence_rationale":"Tier 1-2 — PTM site identified, writer-eraser-reader logic, Co-IP, rescue experiments, multiple methods","pmids":["40195331"],"is_preprint":false},{"year":2025,"finding":"NOTCH1 directly controls BCAT1 expression by binding to the BCAT1 promoter; BCAT1 depletion in NOTCH1-driven T-ALL cells redirected leucine metabolism towards 3-hydroxy butyrate (3-HB) production (an endogenous HDAC inhibitor), altered protein acetylation levels, and sensitized cells to DNA damaging agents.","method":"NOTCH1 gain-of-function retroviral T-ALL model; Bcat1 genetic KO mouse cells; BCAT1 promoter binding by NOTCH1 (ChIP); leucine metabolite profiling; protein acetylation measurement; patient-derived xenograft models with etoposide combination treatment","journal":"Haematologica","confidence":"High","confidence_rationale":"Tier 1-2 — direct promoter binding by ChIP, genetic KO, metabolite profiling, PDX validation","pmids":["39234857"],"is_preprint":false},{"year":2024,"finding":"BCAT1 inhibition in CD4+ T cells blocks production of β-hydroxy β-methylbutyric acid (HMB) via cytosolic leucine catabolism through BCAT1 and HPD/HPDL; HMB upregulates HIF1α mRNA and activates the mTORC1-HIF1α pathway to drive IL-17 production; BCAT1 inhibition reduced EAE severity in vivo.","method":"BCAT1 shRNA knockdown; BCAT1 inhibitor treatment (Bi2, LβhL); HMB supplementation rescue; HIF1α mRNA/protein measurement; IL-17 production assay; EAE mouse model","journal":"Experimental & molecular medicine","confidence":"High","confidence_rationale":"Tier 2 — genetic silencing + pharmacological inhibition + metabolite rescue + in vivo model, multiple orthogonal methods","pmids":["39085353"],"is_preprint":false},{"year":2020,"finding":"BCAT1 binds the RNA-binding protein ZNF423 via its mRNA 3'-UTR AU-rich elements; BCAT1 activates autophagy in hypoxic pulmonary artery smooth muscle cells by binding IRE1 on the ER membrane to activate the XBP-1-RIDD axis, leading to accumulation of BECN1 and Atg5.","method":"Co-immunoprecipitation of BCAT1-IRE1 interaction; ZNF423 RNA pull-down with BCAT1 3'-UTR; BCAT1 knockdown/overexpression; autophagy marker measurement (BECN1, Atg5); hypoxic PASMC model","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2-3 — Co-IP + RNA pull-down, single lab, mechanistic chain partially established","pmids":["32938905"],"is_preprint":false},{"year":2021,"finding":"In lung cancer cells, BCAT1 overexpression depletes α-ketoglutarate and promotes expression of SOX2, a transcription factor for cancer cell stemness and metastasis, thereby promoting metastasis.","method":"Quantitative mass spectrometry; shRNA BCAT1 knockdown reducing metastasis in vitro and in vivo; αKG measurement; SOX2 expression analysis","journal":"Theranostics","confidence":"Medium","confidence_rationale":"Tier 2-3 — proteomics + KD with in vivo validation, mechanistic link (αKG-SOX2) partially established","pmids":["34646394"],"is_preprint":false},{"year":2016,"finding":"DOT1L histone methyltransferase regulates BCAT1 expression through H3K79 methylation; BCAT1 is required downstream of DOT1L for sphere formation and cell migration in breast cancer cells.","method":"DOT1L knockdown/overexpression; H3K79 methylation at BCAT1 locus; BCAT1 KD rescue of DOT1L effects; sphere formation and migration assays","journal":"Biochimie","confidence":"Medium","confidence_rationale":"Tier 2-3 — epigenetic regulation identified with functional epistasis, single lab","pmids":["26783998"],"is_preprint":false},{"year":2018,"finding":"The lncRNA CRNDE acts as a competing endogenous RNA (ceRNA) to sponge miR-203, which directly targets the BCAT1 3'-UTR; CRNDE-mediated inhibition of miR-203 elevates BCAT1 expression and promotes HCC cell proliferation, invasion, and migration.","method":"Dual luciferase reporter assay confirming miR-203 targeting BCAT1 3'-UTR and CRNDE sponging miR-203; CRNDE/miR-203/BCAT1 expression correlation; xenograft model","journal":"Journal of cellular physiology","confidence":"Medium","confidence_rationale":"Tier 2-3 — luciferase reporter + KD experiments + in vivo, single lab","pmids":["30230527"],"is_preprint":false},{"year":2019,"finding":"DNMT1 hypermethylates the miR-124-3p promoter to silence miR-124-3p; miR-124-3p directly targets the BCAT1 mRNA 3'-UTR to suppress BCAT1 expression; DNMT1 knockdown reduces BCAT1 via miR-124-3p restoration in esophageal squamous cell carcinoma.","method":"miR-124-3p 3'-UTR targeting of BCAT1 (luciferase assay inferred); DNMT1 knockdown; miR-124-3p overexpression reducing BCAT1; proliferation/migration assays","journal":"BMC cancer","confidence":"Medium","confidence_rationale":"Tier 3 — mechanistic axis established by KD experiments, single lab","pmids":["31226958"],"is_preprint":false},{"year":2024,"finding":"BCAT1 promotes TNBC progression by maintaining leucine, isoleucine, and valine (BCAA) synthesis; BCAA-supported SHOC2 (a leucine-rich repeat protein) expression activates downstream RAS-ERK signaling; Eupalinolide B (EB) was identified as a direct BCAT1 inhibitor and inhibits SHOC2-RAS-ERK to induce TNBC cell apoptosis.","method":"ABPP technology + pull-down WB + CETSA-WB + MST identifying BCAT1 as direct EB target; HPLC metabolomics; proteomic sequencing; BCAT1 KO/OE with SHOC2-RAS-ERK pathway readout; in vivo mouse models","journal":"Journal of advanced research","confidence":"High","confidence_rationale":"Tier 1-2 — multiple direct target identification methods (ABPP, CETSA, MST) + pathway validation + in vivo","pmids":["39490614"],"is_preprint":false},{"year":2024,"finding":"HuR RNA-binding protein directly binds BCAT1 mRNA and increases its stability and translation, thereby upregulating BCAT1 protein levels; elevated BCAT1 activates ERK5 signaling to promote castration-resistant prostate cancer progression.","method":"RNA immunoprecipitation (RIP) assay; mRNA half-life assay; HuR KO by Cas9; HuR inhibitor KH-3; ERK5 pathway measurement","journal":"Journal of translational medicine","confidence":"Medium","confidence_rationale":"Tier 2 — RIP + mRNA stability assay + genetic KO + pharmacological inhibition, single lab","pmids":["38369471"],"is_preprint":false},{"year":2024,"finding":"In AML cells, high BCAT1 expression limits intracellular αKG levels, which impairs αKG-dependent histone demethylase activity and upregulates H3K9me3; elevated H3K9me3 inhibits ATM expression and blocks DNA damage repair, sensitizing high-BCAT1 AML cells to PARP inhibitors.","method":"BCAT1 KO/OE AML cell lines; αKG measurement; H3K9me3 ChIP; ATM expression; PARP inhibitor sensitivity in vitro and in vivo","journal":"Journal of molecular medicine","confidence":"Medium","confidence_rationale":"Tier 2 — KO/OE + αKG/histone methylation measurements + functional DNA repair readout, single lab","pmids":["38340163"],"is_preprint":false},{"year":2022,"finding":"BCAT1 promotes leukemia development downstream of the P2X1-PBX3 signaling axis; ATP-P2X1 signaling upregulates PBX3 which transactivates BCAT1, and BCAT1 is required to maintain leukemia-initiating cell self-renewal.","method":"P2X1 deletion mouse AML model; PBX3-BCAT1 transactivation; BCAT1 knockdown in human AML cell lines; in vivo transplantation assays","journal":"Leukemia","confidence":"Medium","confidence_rationale":"Tier 2-3 — genetic pathway epistasis in mouse model + human cell lines, single lab","pmids":["36418376"],"is_preprint":false},{"year":2024,"finding":"BCAA/BCAT1 signaling enhances CREB phosphorylation, which is required for maintenance of TKI-resistant CML cells; BCAT1 knockdown dramatically reduces proliferation of TKI-resistant human leukemia lines and abrogates leukemia in BCR-ABL-T315I murine CML model.","method":"BCAT1 knockdown in murine BCR-ABLT315I CML model + human TKI-resistant cell lines; BCAA stimulation; CREB phosphorylation measurement; in vivo transplantation","journal":"Cellular oncology","confidence":"Medium","confidence_rationale":"Tier 2 — genetic KD + pathway readout + in vivo, single lab","pmids":["39412615"],"is_preprint":false},{"year":2025,"finding":"BCAT1 activation in Müller cells under diabetic conditions reduces intracellular αKG, increases H3K4me3 at inflammatory gene (IL-6, TNF-α) promoters, and drives retinal inflammation; Plk4 kinase phosphorylates BCAT1 at threonine 333 to negatively regulate its activity.","method":"ChIP for H3K4me3 at inflammatory gene promoters; targeted metabolomics (αKG measurement); kinase screening identifying Plk4; BCAT1 inhibitor (BAY-069, ERG240) treatment in diabetic mouse models; Bcat1 single-cell expression mapping","journal":"Investigative ophthalmology & visual science","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP + metabolomics + kinase identification + in vivo validation, single lab","pmids":["40530920"],"is_preprint":false},{"year":2024,"finding":"Transcription factor EB (TFEB) transcriptionally regulates BCAT1 expression; TFEB knockdown inhibits BCAA catabolism in pancreatic cancer cells by blocking BCAT1, reducing cell proliferation and metastasis.","method":"TFEB knockdown; BCAT1 expression measurement; BCAA catabolism assays; proliferation and metastasis assays; BCAA deprivation + eltrombopag (TFEB inhibitor) combination","journal":"Cell proliferation","confidence":"Medium","confidence_rationale":"Tier 3 — transcription factor KD with BCAT1 as downstream target, single lab","pmids":["38938061"],"is_preprint":false},{"year":2025,"finding":"NR4A1 nuclear receptor transcriptionally inhibits Bcat1 expression in macrophages; NR4A1 deficiency upregulates Bcat1, which activates the integrated stress response (ISR) in macrophages, promoting vulnerable atherosclerotic plaque formation.","method":"NR4A1 KO mouse (ApoE-/-;NR4A1-/-) vulnerable plaque model; Bcat1 identified as NR4A1 transcriptional target; Bcat1 inhibitor (ERG240) treatment; ISR pathway measurement","journal":"Cellular and molecular life sciences","confidence":"Medium","confidence_rationale":"Tier 2 — genetic KO model + pharmacological inhibition + transcriptional target identification, single lab","pmids":["39985585"],"is_preprint":false},{"year":2024,"finding":"BCAT1 inhibition in trophoblasts blocks NF-κB pathway activation (reducing p-IκBα and nuclear NF-κB p65 translocation), suppresses NLRP3 inflammasome activation, reduces inflammatory cytokine release, and decreases trophoblast apoptosis in LPS-induced inflammation models.","method":"BCATc Inhibitor 2 treatment; EMSA for NF-κB DNA binding; p-IκBα and nuclear NF-κB p65 immunoblot/IF; TUNEL apoptosis assay; cytokine ELISA; LPS-induced mouse pregnancy loss model","journal":"Cell and tissue research","confidence":"Medium","confidence_rationale":"Tier 2-3 — pharmacological inhibition + multiple pathway readouts + in vivo model, single lab","pmids":["39356334"],"is_preprint":false},{"year":2023,"finding":"BCAT1 controls embryonic neural stem cell (NSC) proliferation and differentiation; BCAT1 is specifically highly expressed in layer II/III and IV neurons, and shRNA-mediated BCAT1 suppression reduces NSC proliferation and causes abnormal development of these cortical layers.","method":"Single-cell RNA-seq trajectory analysis; shRNA knockdown of BCAT1 in NSCs; assessment of cortical layer neuron development in vivo","journal":"Molecular brain","confidence":"Medium","confidence_rationale":"Tier 2-3 — scRNA-seq + in vivo shRNA KD with defined developmental phenotype, single lab","pmids":["37344908"],"is_preprint":false},{"year":2022,"finding":"BCAT1 activity is required for ferroptosis protection in myocardial ischemia; BCAT1/BCAT2 overexpression activates the Keap1/Nrf2/HO-1 antioxidant pathway, and BCAT1 or BCAT2 siRNA knockdown promotes ferroptosis and decreases cell viability in cardiomyocytes.","method":"BCAT1/BCAT2 siRNA knockdown; cardiac-specific BCAT1/BCAT2 overexpression in MI mice; Keap1/Nrf2/HO-1 pathway measurement; ferroptosis markers (GPX4, ACSL4); metabolomics identifying BCAT1/BCAT2 as RUS targets","journal":"Antioxidants (Basel, Switzerland)","confidence":"Medium","confidence_rationale":"Tier 2-3 — KD + OE + pathway readout + in vivo, single lab","pmids":["35326233"],"is_preprint":false},{"year":2024,"finding":"BCAT1 expression is regulated by STAT3: mutant IDH1 inhibitor treatment decreases mutant IDH1-STAT3 binding, freeing STAT3 for phosphorylation at Tyr-705 (pSTAT3-Y705) and nuclear translocation, which transcriptionally increases BCAT1 levels; STAT3 knockdown or inhibition attenuates mutant IDH1 inhibitor-mediated BCAT1 upregulation.","method":"STAT3 knockdown; pharmacological STAT3 inhibition; pSTAT3-Y705 immunoblot; nuclear translocation assay; Co-immunoprecipitation of mutant IDH1-STAT3; BCAT1 expression measurement","journal":"Biochimica et biophysica acta. Molecular cell research","confidence":"Medium","confidence_rationale":"Tier 2-3 — Co-IP + KD + nuclear translocation, single lab with multiple methods","pmids":["34329662"],"is_preprint":false}],"current_model":"BCAT1 (cytosolic branched-chain amino acid transaminase 1) catalyzes the reversible transamination of branched-chain amino acids (leucine, isoleucine, valine) with α-ketoglutarate (αKG) to produce glutamate and branched-chain α-keto acids (BCKAs); by consuming αKG it limits TET2/dioxygenase activity and DNA demethylation, while its BCKA products directly activate RhoC GTPase and sustain mTORC1 signaling to drive cell proliferation; additionally, BCAT1 harbors a CXXC redox motif that localizes to mitotic structures to regulate Aurora B kinase centromere localization and ensure faithful chromosome segregation, and its expression is transcriptionally controlled by c-Myc, NOTCH1, STAT3, NR4A1, and TFEB, while its protein stability is regulated by BCKDK-mediated phosphorylation and CHIP/STUB1-mediated ubiquitin-proteasome degradation (counteracted by SIRT5 desuccinylation)."},"narrative":{"teleology":[{"year":1999,"claim":"The earliest functional evidence showed that BCAT1 enzymatic products — specifically the branched-chain keto acid α-ketoisocaproate — have direct biological activity, capable of inducing apoptosis, establishing that BCAT1's downstream metabolites are not inert intermediates.","evidence":"BCAT1 overexpression and α-ketoisocaproate supplementation in murine cells under serum deprivation","pmids":["10471790"],"confidence":"Medium","gaps":["Single lab, not independently replicated","Mechanism of BCKA-induced apoptosis not defined","Physiological relevance of overexpression-level metabolite flux unclear"]},{"year":2004,"claim":"BCAT1 was found to be neuron-specific in the adult brain with differential subcellular localization in glutamatergic versus GABAergic neurons, suggesting a role in neurotransmitter precursor supply.","evidence":"Immunohistochemistry in rat brain with cell-type resolution","pmids":["15329886"],"confidence":"Medium","gaps":["Descriptive localization only; no functional perturbation in neurons","Whether BCAT1 controls neurotransmitter pools was not tested","Human relevance not demonstrated"]},{"year":2013,"claim":"Two studies established BCAT1 as both a critical metabolic dependency in glioblastoma (through glutamate production and proliferation support) and a direct transcriptional target of c-Myc, linking oncogene activation to BCAA catabolism.","evidence":"shRNA knockdown in glioma cells with xenograft validation; ChIP and luciferase reporter assays for c-Myc binding to BCAT1 promoter in nasopharyngeal carcinoma","pmids":["23793099","23758864"],"confidence":"High","gaps":["Whether c-Myc regulation of BCAT1 is universal across cancer types","Identity of downstream metabolic effectors beyond glutamate not resolved"]},{"year":2014,"claim":"Using knockout mice, BCAT1 was shown to control intracellular leucine levels in CD4+ T cells downstream of TCR/calcineurin-NFAT signaling, with BCAT1 loss causing aberrantly elevated mTORC1 activity, revealing BCAT1 as a metabolic rheostat for immune cell activation.","evidence":"BCATc knockout mouse T cells; mTORC1 substrate phosphorylation; glycolysis measurement","pmids":["24847056"],"confidence":"High","gaps":["Whether BCAT1's mTORC1-modulating role is mediated by leucine depletion versus BCKA production","Effects on T cell differentiation and in vivo immune responses not fully characterized"]},{"year":2017,"claim":"A pivotal mechanistic advance showed that BCAT1 controls α-KG availability in AML, directly linking its transaminase activity to epigenetic reprogramming: BCAT1 overexpression depleted α-KG, impaired TET2 dioxygenase activity, and caused DNA hypermethylation phenocopying IDH mutations.","evidence":"BCAT1 knockdown/overexpression in AML cells with metabolomics, DNA methylation profiling, and HIF1α degradation measurement","pmids":["29144447"],"confidence":"High","gaps":["Whether BCAT1's epigenetic effects are sufficient for leukemic transformation alone","Relative contributions of TET2 versus EGLN1/HIF1α pathways downstream of α-KG depletion"]},{"year":2020,"claim":"The metabolic crosstalk axis was expanded to the tumor microenvironment when BCAT1 in cancer-associated fibroblasts was shown to be regulated by TGF-β/SMAD5 signaling, producing BCKAs that are secreted to fuel pancreatic cancer cell metabolism.","evidence":"TGF-β/SMAD5 manipulation in CAFs; isotope tracing of BCAA metabolism; patient-derived material validation","pmids":["32694827"],"confidence":"High","gaps":["Whether BCKA transfer from CAFs to cancer cells involves specific transporters","Quantitative contribution of CAF-derived BCKAs versus cancer cell-autonomous BCAA catabolism"]},{"year":2022,"claim":"A non-metabolic moonlighting function was discovered: BCAT1 localizes to mitotic structures and its CXXC redox motif controls Aurora B kinase centromere localization and chromosome segregation accuracy, independent of its transaminase activity. Separately, the CXXC motif was shown to directly metabolize H₂O₂, conferring intrinsic antioxidant activity.","evidence":"CXXC motif mutagenesis with rescue in cancer cells and iPSCs; purified recombinant BCAT1 H₂O₂ metabolism assay; live-cell imaging and chromosome segregation assays","pmids":["36260995","35453368"],"confidence":"High","gaps":["Structural basis for how CXXC sulfenylation recruits Aurora B","Whether the antioxidant function and mitotic function are mechanistically coupled","Relative contribution of redox versus metabolic functions to tumor growth"]},{"year":2022,"claim":"BCKA products of BCAT1 were established as the critical downstream effectors in GBM, rescuing oxidative phosphorylation, mTORC1 activity, and nucleotide biosynthesis after BCAT1 loss, resolving the question of whether α-KG depletion or BCKA generation is the dominant output.","evidence":"BCAT1 KO with BCKA supplementation rescue in patient-derived GBM models; metabolic measurements including NAD+/NADH and nucleotides","pmids":["35499760"],"confidence":"High","gaps":["Molecular targets of BCKAs that restore mTORC1 and nucleotide synthesis","Whether BCKAs act through allosteric effects, as metabolic fuels, or as signaling molecules"]},{"year":2023,"claim":"The signaling mechanism of BCAT1-derived BCKAs was partly resolved: BCAT1 directly interacts with RhoC GTPase, and BCKAs bind RhoC to activate its GTPase activity, providing a direct metabolite-to-signaling link driving cell motility and metastasis.","evidence":"Co-IP of BCAT1-RhoC; biochemical BCKA-RhoC binding assay; gain-of-function BCAT1-E61A mutant; in vivo metastasis model","pmids":["37337119"],"confidence":"High","gaps":["Structural basis of BCKA-RhoC binding","Whether BCKA-RhoC activation occurs in non-cancer contexts","Specificity for RhoC versus other Rho family GTPases"]},{"year":2024,"claim":"The post-translational regulation of BCAT1 was delineated: BCKDK phosphorylates BCAT1 at S5/S9/T312 to enhance activity and stability; STUB1/CHIP ubiquitinates BCAT1 at K48/K360 for proteasomal degradation; and BCKDK also phosphorylates STUB1-S19 to disrupt its interaction with BCAT1, creating a coherent stabilization circuit.","evidence":"Mass spectrometry phosphosite mapping; Co-IP; ubiquitination and in vitro kinase assays; domain mapping of CHIP-BCAT1 interaction; glioma models","pmids":["38621458","39075053"],"confidence":"High","gaps":["Phosphatases that reverse BCKDK-mediated phosphorylation","Whether BCKDK regulation of BCAT1 is tissue-specific","Crystal structure of BCAT1-CHIP complex"]},{"year":2025,"claim":"SIRT5 was identified as a desuccinylase stabilizing BCAT1 by removing succinylation at K39, which otherwise promotes CHIP-mediated ubiquitination; separately, NOTCH1 and NR4A1 were identified as direct transcriptional regulators of BCAT1 in T-ALL and macrophages respectively, expanding the transcription factor repertoire controlling BCAT1.","evidence":"SIRT5-BCAT1 interaction by proteomics and Co-IP with succinylation site mapping; NOTCH1 ChIP at BCAT1 promoter with genetic KO; NR4A1 KO mouse atherosclerosis model","pmids":["40195331","39234857","39985585"],"confidence":"High","gaps":["Succinylation writer enzyme for BCAT1-K39 unknown","Whether SIRT5-BCAT1 axis operates beyond glioma","Full promoter architecture integrating c-Myc, NOTCH1, STAT3, NR4A1, TFEB inputs"]},{"year":null,"claim":"Key unresolved questions include: the structural basis for BCAT1's CXXC-mediated mitotic and antioxidant functions, how BCKA metabolites allosterically activate diverse targets (RhoC, mTORC1), whether the metabolic and redox moonlighting functions are coordinately regulated in vivo, and the physiological significance of BCAT1 in neuronal BCAA metabolism and neurotransmitter production.","evidence":"","pmids":[],"confidence":"Low","gaps":["No crystal structure of BCAT1 in complex with mitotic or signaling partners","No reconstituted system demonstrating BCKA direct activation of mTORC1","Neuron-specific BCAT1 knockout phenotype not reported"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[0,2,3,10,13]},{"term_id":"GO:0016209","term_label":"antioxidant activity","supporting_discovery_ids":[9,8]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[11,8]}],"localization":[{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[0,2,3]},{"term_id":"GO:0005694","term_label":"chromosome","supporting_discovery_ids":[8]}],"pathway":[{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[0,2,3,10,7]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[3,6,11,24]},{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[2,26]},{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[8]},{"term_id":"R-HSA-9612973","term_label":"Autophagy","supporting_discovery_ids":[12,19]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[14,15,16]}],"complexes":[],"partners":["STUB1","BCKDK","SIRT5","RHOC","IRE1","AURB"],"other_free_text":[]},"mechanistic_narrative":"BCAT1 is the cytosolic branched-chain amino acid transaminase that reversibly transfers α-amino groups from leucine, isoleucine, and valine to α-ketoglutarate, generating glutamate and branched-chain α-keto acids (BCKAs), thereby coupling BCAA catabolism to α-KG availability, mTORC1 signaling, and epigenetic regulation. By consuming α-KG, BCAT1 restricts the activity of α-KG-dependent dioxygenases including TET2 and histone demethylases, driving DNA and histone hypermethylation that phenocopies IDH mutations in AML and glioma [PMID:29144447, PMID:38340163]; its BCKA products directly activate RhoC GTPase to promote cell motility [PMID:37337119] and sustain oxidative phosphorylation and nucleotide biosynthesis required for proliferation [PMID:35499760]. Independent of its transaminase activity, BCAT1 possesses a CXXC redox motif that confers antioxidant H₂O₂-metabolizing capacity and localizes to mitotic structures to regulate Aurora B kinase centromere targeting, ensuring accurate chromosome segregation [PMID:36260995, PMID:35453368]. BCAT1 protein stability is controlled by BCKDK-mediated phosphorylation that antagonizes STUB1/CHIP E3 ubiquitin ligase-dependent K48-linked ubiquitination and proteasomal degradation, a process counteracted by SIRT5 desuccinylation at K39 [PMID:38621458, PMID:39075053, PMID:40195331]."},"prefetch_data":{"uniprot":{"accession":"P54687","full_name":"Branched-chain-amino-acid aminotransferase, cytosolic","aliases":[],"length_aa":386,"mass_kda":43.0,"function":"Catalyzes the first reaction in the catabolism of the essential branched chain amino acids leucine, isoleucine, and valine","subcellular_location":"Cytoplasm","url":"https://www.uniprot.org/uniprotkb/P54687/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/BCAT1","classification":"Not Classified","n_dependent_lines":5,"n_total_lines":1208,"dependency_fraction":0.0041390728476821195},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/BCAT1","total_profiled":1310},"omim":[{"mim_id":"607897","title":"MUSASHI RNA BINDING PROTEIN 2; MSI2","url":"https://www.omim.org/entry/607897"},{"mim_id":"601626","title":"LEUKEMIA, ACUTE MYELOID; AML","url":"https://www.omim.org/entry/601626"},{"mim_id":"113530","title":"BRANCHED-CHAIN AMINOTRANSFERASE 2; BCAT2","url":"https://www.omim.org/entry/113530"},{"mim_id":"113520","title":"BRANCHED-CHAIN AMINOTRANSFERASE 1; BCAT1","url":"https://www.omim.org/entry/113520"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"pancreas","ntpm":54.8}],"url":"https://www.proteinatlas.org/search/BCAT1"},"hgnc":{"alias_symbol":["BCATc"],"prev_symbol":["BCT1"]},"alphafold":{"accession":"P54687","domains":[{"cath_id":"3.30.470.10","chopping":"26-189","consensus_level":"high","plddt":98.2441,"start":26,"end":189},{"cath_id":"3.20.10.10","chopping":"201-373","consensus_level":"high","plddt":97.9701,"start":201,"end":373}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P54687","model_url":"https://alphafold.ebi.ac.uk/files/AF-P54687-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P54687-F1-predicted_aligned_error_v6.png","plddt_mean":94.44},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=BCAT1","jax_strain_url":"https://www.jax.org/strain/search?query=BCAT1"},"sequence":{"accession":"P54687","fasta_url":"https://rest.uniprot.org/uniprotkb/P54687.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P54687/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P54687"}},"corpus_meta":[{"pmid":"23793099","id":"PMC_23793099","title":"BCAT1 promotes cell proliferation through amino acid catabolism in gliomas carrying wild-type IDH1.","date":"2013","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/23793099","citation_count":403,"is_preprint":false},{"pmid":"29144447","id":"PMC_29144447","title":"BCAT1 restricts αKG levels in AML stem cells leading to IDHmut-like DNA hypermethylation.","date":"2017","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/29144447","citation_count":304,"is_preprint":false},{"pmid":"28235484","id":"PMC_28235484","title":"Branched-chain amino acid transaminase 1 (BCAT1) promotes the growth of breast cancer cells through improving mTOR-mediated mitochondrial biogenesis and function.","date":"2017","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/28235484","citation_count":173,"is_preprint":false},{"pmid":"32694827","id":"PMC_32694827","title":"Tumour-reprogrammed stromal BCAT1 fuels branched-chain ketoacid dependency in stromal-rich PDAC tumours.","date":"2020","source":"Nature metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/32694827","citation_count":165,"is_preprint":false},{"pmid":"23758864","id":"PMC_23758864","title":"Over-expression of BCAT1, a c-Myc target gene, induces cell proliferation, migration and invasion in nasopharyngeal carcinoma.","date":"2013","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/23758864","citation_count":127,"is_preprint":false},{"pmid":"26445409","id":"PMC_26445409","title":"Evaluation of an assay for methylated BCAT1 and IKZF1 in plasma for detection of colorectal neoplasia.","date":"2015","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/26445409","citation_count":101,"is_preprint":false},{"pmid":"26372729","id":"PMC_26372729","title":"BCAT1 expression associates with ovarian cancer progression: possible implications in altered disease metabolism.","date":"2015","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/26372729","citation_count":90,"is_preprint":false},{"pmid":"26765125","id":"PMC_26765125","title":"A Blood Test for Methylated BCAT1 and IKZF1 vs. a Fecal Immunochemical Test for Detection of Colorectal Neoplasia.","date":"2016","source":"Clinical and translational gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/26765125","citation_count":87,"is_preprint":false},{"pmid":"27726312","id":"PMC_27726312","title":"A cross-sectional study comparing a blood test for methylated BCAT1 and IKZF1 tumor-derived DNA with CEA for detection of recurrent colorectal cancer.","date":"2016","source":"Cancer medicine","url":"https://pubmed.ncbi.nlm.nih.gov/27726312","citation_count":82,"is_preprint":false},{"pmid":"24847056","id":"PMC_24847056","title":"Cytosolic branched chain aminotransferase (BCATc) regulates mTORC1 signaling and glycolytic metabolism in CD4+ T cells.","date":"2014","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/24847056","citation_count":79,"is_preprint":false},{"pmid":"33568627","id":"PMC_33568627","title":"BCAT1 decreases the sensitivity of cancer cells to cisplatin by regulating mTOR-mediated autophagy via branched-chain amino acid metabolism.","date":"2021","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/33568627","citation_count":79,"is_preprint":false},{"pmid":"15329886","id":"PMC_15329886","title":"Branched-chain amino acids and neurotransmitter metabolism: expression of cytosolic branched-chain aminotransferase (BCATc) in the cerebellum and hippocampus.","date":"2004","source":"The Journal of comparative neurology","url":"https://pubmed.ncbi.nlm.nih.gov/15329886","citation_count":72,"is_preprint":false},{"pmid":"37337119","id":"PMC_37337119","title":"Enhanced BCAT1 activity and BCAA metabolism promotes RhoC activity in cancer progression.","date":"2023","source":"Nature metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/37337119","citation_count":68,"is_preprint":false},{"pmid":"34164393","id":"PMC_34164393","title":"BCAT1 Activates PI3K/AKT/mTOR Pathway and Contributes to the Angiogenesis and Tumorigenicity of Gastric Cancer.","date":"2021","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/34164393","citation_count":53,"is_preprint":false},{"pmid":"30230527","id":"PMC_30230527","title":"LncRNA CRNDE promotes hepatocellular carcinoma cell proliferation, invasion, and migration through regulating miR-203/ BCAT1 axis.","date":"2018","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/30230527","citation_count":47,"is_preprint":false},{"pmid":"26783998","id":"PMC_26783998","title":"DOT1L histone methyltransferase regulates the expression of BCAT1 and is involved in sphere formation and cell migration of breast cancer cell lines.","date":"2016","source":"Biochimie","url":"https://pubmed.ncbi.nlm.nih.gov/26783998","citation_count":47,"is_preprint":false},{"pmid":"10471790","id":"PMC_10471790","title":"Involvement of branched-chain amino acid aminotransferase (Bcat1/Eca39) in apoptosis.","date":"1999","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/10471790","citation_count":46,"is_preprint":false},{"pmid":"35499760","id":"PMC_35499760","title":"Targeting BCAT1 Combined with α-Ketoglutarate Triggers Metabolic Synthetic Lethality in Glioblastoma.","date":"2022","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/35499760","citation_count":45,"is_preprint":false},{"pmid":"31226958","id":"PMC_31226958","title":"The role of DNMT1/hsa-miR-124-3p/BCAT1 pathway in regulating growth and invasion of esophageal squamous cell carcinoma.","date":"2019","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/31226958","citation_count":42,"is_preprint":false},{"pmid":"27698837","id":"PMC_27698837","title":"BCAT1 promotes tumor cell migration and invasion in hepatocellular carcinoma.","date":"2016","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/27698837","citation_count":38,"is_preprint":false},{"pmid":"35760874","id":"PMC_35760874","title":"BCAT1 promotes osteoclast maturation by regulating branched-chain amino acid metabolism.","date":"2022","source":"Experimental & molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/35760874","citation_count":38,"is_preprint":false},{"pmid":"32689462","id":"PMC_32689462","title":"Structure, function and regulation of the cyanobacterial high-affinity bicarbonate transporter, BCT1.","date":"2002","source":"Functional plant biology : FPB","url":"https://pubmed.ncbi.nlm.nih.gov/32689462","citation_count":35,"is_preprint":false},{"pmid":"34646394","id":"PMC_34646394","title":"Proteomic analysis of lung cancer cells reveals a critical role of BCAT1 in cancer cell metastasis.","date":"2021","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/34646394","citation_count":35,"is_preprint":false},{"pmid":"28052414","id":"PMC_28052414","title":"MicroRNA-218 inhibits tumor growth and increases chemosensitivity to CDDP treatment by targeting BCAT1 in prostate cancer.","date":"2017","source":"Molecular carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/28052414","citation_count":34,"is_preprint":false},{"pmid":"35326233","id":"PMC_35326233","title":"Ruscogenin Alleviates Myocardial Ischemia-Induced Ferroptosis through the Activation of BCAT1/BCAT2.","date":"2022","source":"Antioxidants (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/35326233","citation_count":31,"is_preprint":false},{"pmid":"36260995","id":"PMC_36260995","title":"BCAT1 redox function maintains mitotic fidelity.","date":"2022","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/36260995","citation_count":30,"is_preprint":false},{"pmid":"31949641","id":"PMC_31949641","title":"BCAT1 promotes proliferation of endometrial cancer cells through reprogrammed BCAA metabolism.","date":"2018","source":"International journal of clinical and experimental pathology","url":"https://pubmed.ncbi.nlm.nih.gov/31949641","citation_count":30,"is_preprint":false},{"pmid":"32425554","id":"PMC_32425554","title":"BCAT1 Overexpression Promotes Proliferation, Invasion, and Wnt Signaling in Non-Small Cell Lung Cancers.","date":"2020","source":"OncoTargets and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/32425554","citation_count":29,"is_preprint":false},{"pmid":"32958500","id":"PMC_32958500","title":"Evaluation of Circulating Tumor DNA for Methylated BCAT1 and IKZF1 to Detect Recurrence of Stage II/Stage III Colorectal Cancer (CRC).","date":"2020","source":"Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/32958500","citation_count":29,"is_preprint":false},{"pmid":"33484341","id":"PMC_33484341","title":"Oxoeicosanoid receptor inhibition alleviates acute myocardial infarction through activation of BCAT1.","date":"2021","source":"Basic research in cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/33484341","citation_count":28,"is_preprint":false},{"pmid":"35000264","id":"PMC_35000264","title":"Assessment of tumor burden and response to therapy in patients with colorectal cancer using a quantitative ctDNA test for methylated BCAT1/IKZF1.","date":"2022","source":"Molecular oncology","url":"https://pubmed.ncbi.nlm.nih.gov/35000264","citation_count":28,"is_preprint":false},{"pmid":"33478584","id":"PMC_33478584","title":"Evaluation of a panel of tumor-specific differentially-methylated DNA regions in IRF4, IKZF1 and BCAT1 for blood-based detection of colorectal cancer.","date":"2021","source":"Clinical epigenetics","url":"https://pubmed.ncbi.nlm.nih.gov/33478584","citation_count":27,"is_preprint":false},{"pmid":"34984849","id":"PMC_34984849","title":"BCAT1: A risk factor in multiple cancers based on a pan-cancer analysis.","date":"2022","source":"Cancer medicine","url":"https://pubmed.ncbi.nlm.nih.gov/34984849","citation_count":25,"is_preprint":false},{"pmid":"39085353","id":"PMC_39085353","title":"Inhibition of BCAT1-mediated cytosolic leucine metabolism regulates Th17 responses via the mTORC1-HIF1α pathway.","date":"2024","source":"Experimental & molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/39085353","citation_count":24,"is_preprint":false},{"pmid":"32938905","id":"PMC_32938905","title":"BCAT1 binds the RNA-binding protein ZNF423 to activate autophagy via the IRE1-XBP-1-RIDD axis in hypoxic PASMCs.","date":"2020","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/32938905","citation_count":22,"is_preprint":false},{"pmid":"18074675","id":"PMC_18074675","title":"Functional evidence for a nasopharyngeal carcinoma-related gene BCAT1 located at 12p12.","date":"2007","source":"Oncology research","url":"https://pubmed.ncbi.nlm.nih.gov/18074675","citation_count":22,"is_preprint":false},{"pmid":"30265706","id":"PMC_30265706","title":"Branched chain amino acid transaminase 1 (BCAT1) is overexpressed and hypomethylated in patients with non-alcoholic fatty liver disease who experience adverse clinical events: A pilot study.","date":"2018","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/30265706","citation_count":20,"is_preprint":false},{"pmid":"33760210","id":"PMC_33760210","title":"BCAT1 overexpression regulates proliferation and c‑Myc/GLUT1 signaling in head and neck squamous cell carcinoma.","date":"2021","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/33760210","citation_count":20,"is_preprint":false},{"pmid":"38871197","id":"PMC_38871197","title":"BCAT1 alleviates early brain injury by inhibiting ferroptosis through PI3K/AKT/mTOR/GPX4 pathway after subarachnoid hemorrhage.","date":"2024","source":"Free radical biology & medicine","url":"https://pubmed.ncbi.nlm.nih.gov/38871197","citation_count":19,"is_preprint":false},{"pmid":"32855634","id":"PMC_32855634","title":"Silencing of Long Noncoding RNA LINC00324 Interacts with MicroRNA-3200-5p to Attenuate the Tumorigenesis of Gastric Cancer via Regulating BCAT1.","date":"2020","source":"Gastroenterology research and practice","url":"https://pubmed.ncbi.nlm.nih.gov/32855634","citation_count":19,"is_preprint":false},{"pmid":"35453368","id":"PMC_35453368","title":"The BCAT1 CXXC Motif Provides Protection against ROS in Acute Myeloid Leukaemia Cells.","date":"2022","source":"Antioxidants (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/35453368","citation_count":19,"is_preprint":false},{"pmid":"32523652","id":"PMC_32523652","title":"BCATc modulates crosstalk between the PI3K/Akt and the Ras/ERK pathway regulating proliferation in triple negative breast cancer.","date":"2020","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/32523652","citation_count":18,"is_preprint":false},{"pmid":"34249421","id":"PMC_34249421","title":"BCAT1 knockdown-mediated suppression of melanoma cell proliferation and migration is associated with reduced oxidative phosphorylation.","date":"2021","source":"American journal of cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/34249421","citation_count":18,"is_preprint":false},{"pmid":"33744853","id":"PMC_33744853","title":"Flotillin-2 promotes cell proliferation via activating the c-Myc/BCAT1 axis by suppressing miR-33b-5p in nasopharyngeal carcinoma.","date":"2021","source":"Aging","url":"https://pubmed.ncbi.nlm.nih.gov/33744853","citation_count":18,"is_preprint":false},{"pmid":"36386234","id":"PMC_36386234","title":"BCATc inhibitor 2 ameliorated mitochondrial dysfunction and apoptosis in oleic acid-induced non-alcoholic fatty liver disease model.","date":"2022","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/36386234","citation_count":17,"is_preprint":false},{"pmid":"32269179","id":"PMC_32269179","title":"USF1-mediated upregulation of lncRNA GAS6-AS2 facilitates osteosarcoma progression through miR-934/BCAT1 axis.","date":"2020","source":"Aging","url":"https://pubmed.ncbi.nlm.nih.gov/32269179","citation_count":17,"is_preprint":false},{"pmid":"32273770","id":"PMC_32273770","title":"LINC00963 Confers Oncogenic Properties in Glioma by Regulating the miR-506/BCAT1 Axis.","date":"2020","source":"Cancer management and research","url":"https://pubmed.ncbi.nlm.nih.gov/32273770","citation_count":17,"is_preprint":false},{"pmid":"34370878","id":"PMC_34370878","title":"Long non-coding RNA TMPO-AS1 facilitates the progression of colorectal cancer cells via sponging miR-98-5p to upregulate BCAT1 expression.","date":"2021","source":"Journal of gastroenterology and hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/34370878","citation_count":16,"is_preprint":false},{"pmid":"30427175","id":"PMC_30427175","title":"Gabapentin Can Suppress Cell Proliferation Independent of the Cytosolic Branched-Chain Amino Acid Transferase 1 (BCAT1).","date":"2018","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/30427175","citation_count":16,"is_preprint":false},{"pmid":"36644500","id":"PMC_36644500","title":"The emerging role of the branched chain aminotransferases, BCATc and BCATm, for anti-tumor T-cell immunity.","date":"2023","source":"Immunometabolism (Cobham, Surrey)","url":"https://pubmed.ncbi.nlm.nih.gov/36644500","citation_count":15,"is_preprint":false},{"pmid":"35562710","id":"PMC_35562710","title":"Impaired expression of BCAT1 relates to muscle atrophy of mouse model of sarcopenia.","date":"2022","source":"BMC musculoskeletal disorders","url":"https://pubmed.ncbi.nlm.nih.gov/35562710","citation_count":15,"is_preprint":false},{"pmid":"34109436","id":"PMC_34109436","title":"Curcumin induces apoptosis by inhibiting BCAT1 expression and mTOR signaling in cytarabine‑resistant myeloid leukemia cells.","date":"2021","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/34109436","citation_count":15,"is_preprint":false},{"pmid":"31788061","id":"PMC_31788061","title":"Data mining of the expression and regulatory role of BCAT1 in hepatocellular carcinoma.","date":"2019","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/31788061","citation_count":15,"is_preprint":false},{"pmid":"28416735","id":"PMC_28416735","title":"Reciprocal control of lncRNA-BCAT1 and β-catenin pathway reveals lncRNA-BCAT1 long non-coding RNA acts as a tumor suppressor in colorectal cancer.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/28416735","citation_count":15,"is_preprint":false},{"pmid":"38621458","id":"PMC_38621458","title":"Cross-talk between BCKDK-mediated phosphorylation and STUB1-dependent ubiquitination degradation of BCAT1 promotes GBM progression.","date":"2024","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/38621458","citation_count":14,"is_preprint":false},{"pmid":"35290664","id":"PMC_35290664","title":"Detection of recurrent colorectal cancer with high specificity using a reporting threshold for circulating tumor DNA methylated in BCAT1 and IKZF1.","date":"2022","source":"Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/35290664","citation_count":14,"is_preprint":false},{"pmid":"34329662","id":"PMC_34329662","title":"Mutant IDH1 inhibitors activate pSTAT3-Y705 leading to an increase in BCAT1 and YKL-40 levels in mutant IDH1-expressing cells.","date":"2021","source":"Biochimica et biophysica acta. Molecular cell research","url":"https://pubmed.ncbi.nlm.nih.gov/34329662","citation_count":14,"is_preprint":false},{"pmid":"15233768","id":"PMC_15233768","title":"Intraocular delivery of BDNF following visual cortex lesion upregulates cytosolic branched chain aminotransferase (BCATc) in the rat dorsal lateral geniculate nucleus.","date":"2004","source":"The European journal of neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/15233768","citation_count":14,"is_preprint":false},{"pmid":"35776379","id":"PMC_35776379","title":"Circular RNA VPS18 Promotes Glioblastoma Progression by Regulating miR-1229-3p/BCAT1 Axis.","date":"2022","source":"Neurotoxicity research","url":"https://pubmed.ncbi.nlm.nih.gov/35776379","citation_count":13,"is_preprint":false},{"pmid":"39490614","id":"PMC_39490614","title":"Small-molecule targeting BCAT1-mediated BCAA metabolism inhibits the activation of SHOC2-RAS-ERK to induce apoptosis of Triple-negative breast cancer cells.","date":"2024","source":"Journal of advanced research","url":"https://pubmed.ncbi.nlm.nih.gov/39490614","citation_count":13,"is_preprint":false},{"pmid":"27626306","id":"PMC_27626306","title":"Assessment of bevacizumab resistance increased by expression of BCAT1 in IDH1 wild-type glioblastoma: application of DSC perfusion MR imaging.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27626306","citation_count":13,"is_preprint":false},{"pmid":"35318805","id":"PMC_35318805","title":"Identification of natural compounds tubercidin and lycorine HCl against small-cell lung cancer and BCAT1 as a therapeutic target.","date":"2022","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/35318805","citation_count":13,"is_preprint":false},{"pmid":"36111572","id":"PMC_36111572","title":"BCAT1 promotes lung adenocarcinoma progression through enhanced mitochondrial function and NF-κB pathway activation.","date":"2022","source":"Journal of Zhejiang University. Science. B","url":"https://pubmed.ncbi.nlm.nih.gov/36111572","citation_count":12,"is_preprint":false},{"pmid":"36418376","id":"PMC_36418376","title":"P2X1 enhances leukemogenesis through PBX3-BCAT1 pathways.","date":"2022","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/36418376","citation_count":12,"is_preprint":false},{"pmid":"14563018","id":"PMC_14563018","title":"Lrmp and Bcat1 are candidates for the type I diabetes susceptibility locus Idd6.","date":"2003","source":"Autoimmunity","url":"https://pubmed.ncbi.nlm.nih.gov/14563018","citation_count":12,"is_preprint":false},{"pmid":"35253733","id":"PMC_35253733","title":"Detection of hypermethylated BCAT1 and IKZF1 DNA in blood and tissues of colorectal, breast and prostate cancer patients.","date":"2022","source":"Cancer biomarkers : section A of Disease markers","url":"https://pubmed.ncbi.nlm.nih.gov/35253733","citation_count":12,"is_preprint":false},{"pmid":"32630973","id":"PMC_32630973","title":"Validation of a Circulating Tumor-Derived DNA Blood Test for Detection of Methylated BCAT1 and IKZF1 DNA.","date":"2017","source":"The journal of applied laboratory medicine","url":"https://pubmed.ncbi.nlm.nih.gov/32630973","citation_count":12,"is_preprint":false},{"pmid":"38938061","id":"PMC_38938061","title":"Transcription factor EB reprograms branched-chain amino acid metabolism and promotes pancreatic cancer progression via transcriptional regulation of BCAT1.","date":"2024","source":"Cell proliferation","url":"https://pubmed.ncbi.nlm.nih.gov/38938061","citation_count":11,"is_preprint":false},{"pmid":"30113684","id":"PMC_30113684","title":"Loss of BCAT1 Expression is a Sensitive Marker for IDH-Mutant Diffuse Glioma.","date":"2019","source":"Neurosurgery","url":"https://pubmed.ncbi.nlm.nih.gov/30113684","citation_count":11,"is_preprint":false},{"pmid":"17150414","id":"PMC_17150414","title":"Expression of cytosolic branched chain aminotransferase (BCATc) mRNA in the developing mouse brain.","date":"2006","source":"Gene expression patterns : GEP","url":"https://pubmed.ncbi.nlm.nih.gov/17150414","citation_count":10,"is_preprint":false},{"pmid":"37705956","id":"PMC_37705956","title":"LncRNA THUMPD3-AS1 promotes invasion and EMT in gastric cancer by regulating the miR-1297/BCAT1 pathway.","date":"2023","source":"iScience","url":"https://pubmed.ncbi.nlm.nih.gov/37705956","citation_count":10,"is_preprint":false},{"pmid":"36123616","id":"PMC_36123616","title":"Translation of a tissue epigenetic signature to circulating free DNA suggests BCAT1 as a potential noninvasive diagnostic biomarker for lung cancer.","date":"2022","source":"Clinical epigenetics","url":"https://pubmed.ncbi.nlm.nih.gov/36123616","citation_count":10,"is_preprint":false},{"pmid":"30310175","id":"PMC_30310175","title":"BCAT1 and miR-2504: novel methylome signature distinguishes spindle/desmoplastic melanoma from superficial malignant peripheral nerve sheath tumor.","date":"2018","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/30310175","citation_count":10,"is_preprint":false},{"pmid":"38644767","id":"PMC_38644767","title":"BCAT1, IKZF1 and SEPT9: methylated DNA biomarkers for detection of pan-gastrointestinal adenocarcinomas.","date":"2024","source":"Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals","url":"https://pubmed.ncbi.nlm.nih.gov/38644767","citation_count":9,"is_preprint":false},{"pmid":"16828066","id":"PMC_16828066","title":"Cytosolic branched chain aminotransferase (BCATc) mRNA is up-regulated in restricted brain areas of BDNF transgenic mice.","date":"2006","source":"Brain research","url":"https://pubmed.ncbi.nlm.nih.gov/16828066","citation_count":9,"is_preprint":false},{"pmid":"38776254","id":"PMC_38776254","title":"Engineering the cyanobacterial ATP-driven BCT1 bicarbonate transporter for functional targeting to C3 plant chloroplasts.","date":"2024","source":"Journal of experimental botany","url":"https://pubmed.ncbi.nlm.nih.gov/38776254","citation_count":9,"is_preprint":false},{"pmid":"39234857","id":"PMC_39234857","title":"BCAT1 is a NOTCH1 target and sustains the oncogenic function of NOTCH1.","date":"2025","source":"Haematologica","url":"https://pubmed.ncbi.nlm.nih.gov/39234857","citation_count":8,"is_preprint":false},{"pmid":"30378334","id":"PMC_30378334","title":"[The Expression and Significance of c-myc and bcat1 in Cervical Cancer].","date":"2018","source":"Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition","url":"https://pubmed.ncbi.nlm.nih.gov/30378334","citation_count":8,"is_preprint":false},{"pmid":"36182869","id":"PMC_36182869","title":"The proatherosclerotic function of BCAT1 in atherosclerosis development of aged-apolipoprotein E-deficient mice.","date":"2022","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/36182869","citation_count":7,"is_preprint":false},{"pmid":"39455853","id":"PMC_39455853","title":"Aberrant BCAT1 expression augments MTOR activity and accelerates disease progression in chronic lymphocytic leukemia.","date":"2024","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/39455853","citation_count":6,"is_preprint":false},{"pmid":"38340163","id":"PMC_38340163","title":"High expression of BCAT1 sensitizes AML cells to PARP inhibitor by suppressing DNA damage response.","date":"2024","source":"Journal of molecular medicine (Berlin, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/38340163","citation_count":6,"is_preprint":false},{"pmid":"40195331","id":"PMC_40195331","title":"SIRT5-mediated BCAT1 desuccinylation and stabilization leads to ferroptosis insensitivity and promotes cell proliferation in glioma.","date":"2025","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/40195331","citation_count":6,"is_preprint":false},{"pmid":"38235619","id":"PMC_38235619","title":"LncRNA PSMB8-AS1 increases glioma malignancy via the miR-382-3p/BCAT1 axis.","date":"2023","source":"Translational oncology","url":"https://pubmed.ncbi.nlm.nih.gov/38235619","citation_count":6,"is_preprint":false},{"pmid":"33500319","id":"PMC_33500319","title":"Variables Associated with Detection of Methylated BCAT1 or IKZF1 in Blood from Patients Without Colonoscopically Evident Colorectal Cancer.","date":"2021","source":"Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/33500319","citation_count":6,"is_preprint":false},{"pmid":"39356334","id":"PMC_39356334","title":"Inhibition of BCAT1 expression improves recurrent miscarriage by regulating cellular dysfunction and inflammation of trophoblasts.","date":"2024","source":"Cell and tissue research","url":"https://pubmed.ncbi.nlm.nih.gov/39356334","citation_count":5,"is_preprint":false},{"pmid":"39075053","id":"PMC_39075053","title":"CHIP-mediated ubiquitin degradation of BCAT1 regulates glioma cell proliferation and temozolomide sensitivity.","date":"2024","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/39075053","citation_count":5,"is_preprint":false},{"pmid":"37344908","id":"PMC_37344908","title":"BCAT1 controls embryonic neural stem cells proliferation and differentiation in the upper layer neurons.","date":"2023","source":"Molecular brain","url":"https://pubmed.ncbi.nlm.nih.gov/37344908","citation_count":5,"is_preprint":false},{"pmid":"38369471","id":"PMC_38369471","title":"HuR promotes castration-resistant prostate cancer progression by altering ERK5 activation via posttranscriptional regulation of BCAT1.","date":"2024","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/38369471","citation_count":5,"is_preprint":false},{"pmid":"39412615","id":"PMC_39412615","title":"BCAT1 contributes to the development of TKI-resistant CML.","date":"2024","source":"Cellular oncology (Dordrecht, Netherlands)","url":"https://pubmed.ncbi.nlm.nih.gov/39412615","citation_count":5,"is_preprint":false},{"pmid":"31465797","id":"PMC_31465797","title":"BCAT1 and BCAT2 disruption in CHO cells has cell line-dependent effects.","date":"2019","source":"Journal of biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/31465797","citation_count":4,"is_preprint":false},{"pmid":"35788291","id":"PMC_35788291","title":"Driving with Both Feet: Supplementing AKG While Inhibiting BCAT1 Leads to Synthetic Lethality in GBM.","date":"2022","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/35788291","citation_count":4,"is_preprint":false},{"pmid":"39324007","id":"PMC_39324007","title":"Identify BCAT1 plays an oncogenic role and promotes EMT in KIRC via single cell RNA-seq and experiment.","date":"2024","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/39324007","citation_count":4,"is_preprint":false},{"pmid":"39056279","id":"PMC_39056279","title":"BCAT1 promotes cell proliferation, migration, and invasion via the PI3K-Akt signaling pathway in oral squamous cell carcinoma.","date":"2024","source":"Oral diseases","url":"https://pubmed.ncbi.nlm.nih.gov/39056279","citation_count":4,"is_preprint":false},{"pmid":"30069041","id":"PMC_30069041","title":"Author Correction: BCAT1 restricts αKG levels in AML stem cells leading to IDHmut-like DNA hypermethylation.","date":"2018","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/30069041","citation_count":4,"is_preprint":false},{"pmid":"40530920","id":"PMC_40530920","title":"BCAT1 Activation Reprograms Branched-Chain Amino Acid Metabolism and Epigenetically Promotes Inflammation in Diabetic Retinopathy.","date":"2025","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/40530920","citation_count":3,"is_preprint":false},{"pmid":"37591221","id":"PMC_37591221","title":"MiR-320a Acts as a Tumor Suppressor in Somatotroph Pituitary Neuroendocrine Tumors by Targeting BCAT1.","date":"2023","source":"Neuroendocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/37591221","citation_count":3,"is_preprint":false},{"pmid":"37700640","id":"PMC_37700640","title":"Knockdown of PRMT1 suppresses the malignant biological behavior of osteosarcoma cells and increases cisplatin sensitivity via c-Myc-mediated BCAT1 downregulation.","date":"2023","source":"Journal of biochemical and molecular toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/37700640","citation_count":3,"is_preprint":false},{"pmid":"40005214","id":"PMC_40005214","title":"Design, Synthesis and Biological Activity Study of γ-Aminobutyric Acid (GABA) Derivatives Containing Bridged Bicyclic Skeletons as BCAT1 Inhibitors.","date":"2025","source":"Molecules (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/40005214","citation_count":3,"is_preprint":false},{"pmid":"39154541","id":"PMC_39154541","title":"A blood test measuring DNA methylation of BCAT1 and IKZF1 for detection of lung adenocarcinoma.","date":"2024","source":"Cancer treatment and research communications","url":"https://pubmed.ncbi.nlm.nih.gov/39154541","citation_count":2,"is_preprint":false},{"pmid":"39985585","id":"PMC_39985585","title":"NR4A1 deficiency promotes carotid plaque vulnerability by activating integrated stress response via targeting Bcat1.","date":"2025","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/39985585","citation_count":2,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":54042,"output_tokens":9188,"usd":0.149973},"stage2":{"model":"claude-opus-4-6","input_tokens":13152,"output_tokens":3502,"usd":0.229965},"total_usd":0.379938,"stage1_batch_id":"msgbatch_01TqNM6p6FsoMBT2jzQTwKBr","stage2_batch_id":"msgbatch_01Ya473eco8sTHbvRymQaU8o","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2013,\n      \"finding\": \"BCAT1 initiates BCAA catabolism in glioblastoma cells; suppression of BCAT1 blocked glutamate excretion, reduced proliferation and invasiveness in vitro, and decreased tumor growth in xenograft models, establishing BCAT1 as required for glioma cell proliferation through amino acid catabolism.\",\n      \"method\": \"shRNA knockdown in glioma cell lines + xenograft model; metabolite measurements (glutamate excretion); ectopic mutant IDH1 overexpression suppressing BCAT1\",\n      \"journal\": \"Nature medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean KD with defined metabolic and cellular phenotype, replicated in vivo, multiple orthogonal methods\",\n      \"pmids\": [\"23793099\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"c-Myc directly binds the BCAT1 promoter and transcriptionally upregulates BCAT1 expression in nasopharyngeal carcinoma cells, as demonstrated by ChIP and luciferase reporter assays.\",\n      \"method\": \"ChIP assay; luciferase reporter assay; c-Myc siRNA knockdown reducing BCAT1 expression\",\n      \"journal\": \"Molecular cancer\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1/2 — ChIP + luciferase reporter + siRNA knockdown, multiple orthogonal methods in single study\",\n      \"pmids\": [\"23758864\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"BCAT1 transfers α-amino groups from BCAAs to α-ketoglutarate (αKG), thereby restricting intracellular αKG levels in AML stem cells; BCAT1 knockdown caused αKG accumulation leading to EGLN1-mediated HIF1α degradation; BCAT1 overexpression decreased αKG and caused TET2-dependent DNA hypermethylation, mimicking IDH mutation effects.\",\n      \"method\": \"BCAT1 knockdown/overexpression in AML cells; metabolomics (intracellular αKG measurement); proteomic analysis; DNA methylation profiling; HIF1α protein level measurement\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal methods (metabolomics, proteomics, epigenomics), gain- and loss-of-function, strong mechanistic chain established\",\n      \"pmids\": [\"29144447\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"BCATc (BCAT1) expression is induced by T cell receptor (TCR) signaling via the calcineurin-NFAT pathway in CD4+ T cells; BCATc controls intracellular leucine levels, and its absence increases mTORC1 activation (elevated S6 and 4EBP-1 phosphorylation) and glycolytic metabolism.\",\n      \"method\": \"BCATc knockout mouse; cyclosporin A (calcineurin-NFAT inhibitor) treatment; leucine transamination assay; mTORC1 substrate phosphorylation (immunoblot); glycolysis measurement (Seahorse)\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — genetic KO model + pharmacological inhibition + biochemical assays, multiple orthogonal methods\",\n      \"pmids\": [\"24847056\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"BCATc (BCAT1) is exclusively expressed in neurons (not astrocytes) in the adult rat brain; in glutamatergic neurons it localizes to axons and nerve terminals, while in GABAergic neurons it concentrates in cell bodies, suggesting a role in regulating glutamate available for neurotransmitter release or GABA synthesis.\",\n      \"method\": \"Immunohistochemistry in rat brain; cell-type-specific localization in cerebellum and hippocampus\",\n      \"journal\": \"The Journal of comparative neurology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — direct localization by IHC with functional interpretation, single study\",\n      \"pmids\": [\"15329886\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Overexpression of BCAT1/ECA39 in murine cells promotes apoptosis under serum deprivation; the branched-chain keto acid α-ketoisocaproate (product of leucine catabolism by BCAT1) can independently induce rapid apoptotic cell death, suggesting the apoptotic effect is mediated by BCAA-derived keto acid metabolites.\",\n      \"method\": \"Overexpression of BCAT1 in murine cells; serum deprivation assay; α-ketoisocaproate treatment; cell viability/apoptosis assays\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — gain-of-function + metabolite supplementation with defined phenotypic readout (apoptosis), single lab\",\n      \"pmids\": [\"10471790\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"BCAT1 promotes breast cancer cell growth by activating mTOR signaling, enhancing mitochondrial biogenesis and ATP production, and suppressing mitochondrial ROS; this effect is specific to mTOR (not AMPK or SIRT1).\",\n      \"method\": \"BCAT1 knockdown/overexpression in breast cancer cells; mTOR pathway inhibitor; colony formation; mitochondrial biogenesis and ATP production assays\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — KD/OE with pathway inhibitor rescue, single lab\",\n      \"pmids\": [\"28235484\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"In pancreatic ductal adenocarcinoma, TGF-β signaling via the SMAD5 axis directly targets BCAT1 in cancer-associated fibroblasts (CAFs), dictating internalization of extracellular matrix to supply amino acid precursors for branched-chain α-ketoacid (BCKA) secretion by CAFs that fuels PDAC cancer cells.\",\n      \"method\": \"TGF-β/SMAD5 pathway manipulation in CAFs; isotope tracing of BCAA metabolism; BCAT1 knockdown in CAFs; CTC and PDAC tissue slice validation\",\n      \"journal\": \"Nature metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — pathway epistasis (TGF-β-SMAD5-BCAT1), isotope tracing, multiple model systems including patient-derived material\",\n      \"pmids\": [\"32694827\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"BCAT1 localizes to mitotic structures and has a non-metabolic moonlighting function as a mitotic regulator; its CXXC redox motif controls cysteine sulfenylation in mitotic cells, promoting Aurora kinase B localization to centromeres and securing accurate chromosome segregation.\",\n      \"method\": \"Gene knockout and rescue strategies in cancer cells and iPSCs; live cell imaging of BCAT1 at mitotic structures; CXXC motif mutagenesis; Aurora B localization by immunofluorescence; chromosome segregation assays; cerebral organoid and mouse syngraft tumor growth models\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — reconstitution of function by rescue with wild-type vs. CXXC mutant, multiple orthogonal assays, in vivo validation\",\n      \"pmids\": [\"36260995\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"The BCAT1 CXXC motif has antioxidant activity: purified wild-type BCAT1 protein can metabolize H2O2 in vitro, whereas CXXC motif mutant BCAT1 or wild-type BCAT2 cannot; this activity buffers intracellular ROS in AML cells and reduces myeloid differentiation markers.\",\n      \"method\": \"In vitro H2O2 metabolism assay with purified recombinant BCAT1 wild-type vs. CXXS mutant; intracellular ROS measurement in U937 AML cells overexpressing WT vs. CXXS BCAT1; myeloid differentiation markers (CD11b, CD14, CD68, CD36)\",\n      \"journal\": \"Antioxidants (Basel, Switzerland)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution with purified protein + mutagenesis + cellular validation\",\n      \"pmids\": [\"35453368\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Loss of BCAT1 in IDH-wildtype GBM cells increases NAD+/NADH ratio but impairs oxidative phosphorylation, mTORC1 activity, and nucleotide biosynthesis; supplementation with branched-chain α-ketoacids (BCKA, downstream products of BCAT1) rescues these defects and prevents cell death, establishing BCAT1-generated BCKAs as the critical downstream mediators.\",\n      \"method\": \"BCAT1 inhibitor (gabapentin) + αKG co-treatment synthetic lethality screen; BCAT1 KO + BCKA supplementation rescue; patient-derived GBM in vitro and in vivo models; metabolic measurements (NAD+/NADH, nucleotides, ATP, mTORC1 substrates)\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — metabolic synthetic lethal screen + KO + metabolite rescue + in vivo validation, multiple orthogonal methods\",\n      \"pmids\": [\"35499760\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"BCAT1 directly interacts with RhoC GTPase, elevating RhoC activity; additionally, BCAA-derived branched-chain α-keto acids (BCKAs) directly bind to RhoC and promote its GTPase activity, linking BCAT1 enzymatic activity to cell motility through RhoC activation.\",\n      \"method\": \"Co-immunoprecipitation of BCAT1-RhoC interaction; BCKA direct binding to RhoC (biochemical binding assay); BCAT1 gain-of-function mutation (E61A) with higher enzymatic activity; BCAT1 KO rescue with BCAT1-E61A or BCKA supplementation; in vivo peritoneal metastasis model; candesartan identified as BCAT1-E61A inhibitor\",\n      \"journal\": \"Nature metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — direct protein interaction (Co-IP), direct metabolite-protein binding, gain-of-function mutagenesis, rescue experiments, in vivo validation\",\n      \"pmids\": [\"37337119\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"BCAT1 increases cisplatin resistance in cancer cells by inducing mTOR-mediated autophagy via leucine metabolism; cisplatin upregulates BCAT1, which decreases leucine availability to suppress mTOR signaling and activate autophagy, thereby reducing cisplatin sensitivity.\",\n      \"method\": \"BCAT1 knockdown/overexpression; leucine and BCAA supplementation rescuing mTOR activity and autophagy; chloroquine (autophagy inhibitor) in vivo; mTOR substrate phosphorylation assays\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — KD/OE + metabolite rescue + in vivo, single lab with multiple methods\",\n      \"pmids\": [\"33568627\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"BCAT1 promotes osteoclast maturation through its enzymatic BCAA catabolism activity; enzymatically dead BCAT1 abrogated osteoclast maturation, and the specific BCAT1 inhibitor gabapentin reduced osteoclast differentiation and inhibited LPS-induced bone loss in mice.\",\n      \"method\": \"Expression of enzymatically dead BCAT1 mutant; gabapentin (BCAT1 inhibitor) treatment; in vitro RANKL-induced osteoclast differentiation assay; in vivo LPS-induced calvaria bone loss model\",\n      \"journal\": \"Experimental & molecular medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — catalytic dead mutant + pharmacological inhibition + in vivo model; enzymatic activity specifically required\",\n      \"pmids\": [\"35760874\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"BCKDK phosphorylates BCAT1 at S5, S9, and T312, increasing its catalytic and antioxidant activity and stability; STUB1 is an E3 ubiquitin ligase for BCAT1 that promotes K48-linked ubiquitin degradation of BCAT1; BCKDK phosphorylation of STUB1 at S19 disrupts its interaction with BCAT1, thereby inhibiting BCAT1 ubiquitination and degradation.\",\n      \"method\": \"Mass spectrometry identification of phosphorylation sites; co-immunoprecipitation of BCKDK-BCAT1 and STUB1-BCAT1; mutagenesis of phosphorylation sites; ubiquitination assay; in vitro kinase assay; in vivo xenograft model\",\n      \"journal\": \"Cancer letters\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — phosphorylation site mapping by MS + mutagenesis + Co-IP + ubiquitination assay, multiple orthogonal methods\",\n      \"pmids\": [\"38621458\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"CHIP (STUB1) E3 ubiquitin ligase interacts with BCAT1 via its coiled-coil domain, promoting K48-linked ubiquitination and proteasomal degradation of BCAT1 at K360; reduced CHIP expression leads to high BCAT1 in glioma cells, and CHIP-mediated BCAT1 degradation reduces glutathione synthesis, increases oxidative stress, and sensitizes glioma cells to temozolomide.\",\n      \"method\": \"Co-immunoprecipitation of CHIP-BCAT1; domain mapping (CC domain); ubiquitination site mutagenesis (K360); proteasome inhibitor treatment; GSH measurement; in vitro and in vivo glioma models\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — Co-IP + domain mapping + site mutagenesis + functional rescue, multiple orthogonal methods\",\n      \"pmids\": [\"39075053\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"SIRT5 desuccinylates BCAT1 at K39, preventing its interaction with the E3 ligase CHIP and thereby stabilizing BCAT1 protein against ubiquitin-proteasome degradation, leading to increased BCAA catabolism, ferroptosis resistance, and glioma cell proliferation.\",\n      \"method\": \"Proteomics/metabolomics identifying BCAT1 as SIRT5 substrate; succinylation site mapping at K39; co-immunoprecipitation of BCAT1-CHIP interaction; SIRT5 knockdown + BCAT1 overexpression rescue; in vitro and in vivo glioma models\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — PTM site identified, writer-eraser-reader logic, Co-IP, rescue experiments, multiple methods\",\n      \"pmids\": [\"40195331\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"NOTCH1 directly controls BCAT1 expression by binding to the BCAT1 promoter; BCAT1 depletion in NOTCH1-driven T-ALL cells redirected leucine metabolism towards 3-hydroxy butyrate (3-HB) production (an endogenous HDAC inhibitor), altered protein acetylation levels, and sensitized cells to DNA damaging agents.\",\n      \"method\": \"NOTCH1 gain-of-function retroviral T-ALL model; Bcat1 genetic KO mouse cells; BCAT1 promoter binding by NOTCH1 (ChIP); leucine metabolite profiling; protein acetylation measurement; patient-derived xenograft models with etoposide combination treatment\",\n      \"journal\": \"Haematologica\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — direct promoter binding by ChIP, genetic KO, metabolite profiling, PDX validation\",\n      \"pmids\": [\"39234857\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"BCAT1 inhibition in CD4+ T cells blocks production of β-hydroxy β-methylbutyric acid (HMB) via cytosolic leucine catabolism through BCAT1 and HPD/HPDL; HMB upregulates HIF1α mRNA and activates the mTORC1-HIF1α pathway to drive IL-17 production; BCAT1 inhibition reduced EAE severity in vivo.\",\n      \"method\": \"BCAT1 shRNA knockdown; BCAT1 inhibitor treatment (Bi2, LβhL); HMB supplementation rescue; HIF1α mRNA/protein measurement; IL-17 production assay; EAE mouse model\",\n      \"journal\": \"Experimental & molecular medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic silencing + pharmacological inhibition + metabolite rescue + in vivo model, multiple orthogonal methods\",\n      \"pmids\": [\"39085353\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"BCAT1 binds the RNA-binding protein ZNF423 via its mRNA 3'-UTR AU-rich elements; BCAT1 activates autophagy in hypoxic pulmonary artery smooth muscle cells by binding IRE1 on the ER membrane to activate the XBP-1-RIDD axis, leading to accumulation of BECN1 and Atg5.\",\n      \"method\": \"Co-immunoprecipitation of BCAT1-IRE1 interaction; ZNF423 RNA pull-down with BCAT1 3'-UTR; BCAT1 knockdown/overexpression; autophagy marker measurement (BECN1, Atg5); hypoxic PASMC model\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — Co-IP + RNA pull-down, single lab, mechanistic chain partially established\",\n      \"pmids\": [\"32938905\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"In lung cancer cells, BCAT1 overexpression depletes α-ketoglutarate and promotes expression of SOX2, a transcription factor for cancer cell stemness and metastasis, thereby promoting metastasis.\",\n      \"method\": \"Quantitative mass spectrometry; shRNA BCAT1 knockdown reducing metastasis in vitro and in vivo; αKG measurement; SOX2 expression analysis\",\n      \"journal\": \"Theranostics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — proteomics + KD with in vivo validation, mechanistic link (αKG-SOX2) partially established\",\n      \"pmids\": [\"34646394\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"DOT1L histone methyltransferase regulates BCAT1 expression through H3K79 methylation; BCAT1 is required downstream of DOT1L for sphere formation and cell migration in breast cancer cells.\",\n      \"method\": \"DOT1L knockdown/overexpression; H3K79 methylation at BCAT1 locus; BCAT1 KD rescue of DOT1L effects; sphere formation and migration assays\",\n      \"journal\": \"Biochimie\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — epigenetic regulation identified with functional epistasis, single lab\",\n      \"pmids\": [\"26783998\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"The lncRNA CRNDE acts as a competing endogenous RNA (ceRNA) to sponge miR-203, which directly targets the BCAT1 3'-UTR; CRNDE-mediated inhibition of miR-203 elevates BCAT1 expression and promotes HCC cell proliferation, invasion, and migration.\",\n      \"method\": \"Dual luciferase reporter assay confirming miR-203 targeting BCAT1 3'-UTR and CRNDE sponging miR-203; CRNDE/miR-203/BCAT1 expression correlation; xenograft model\",\n      \"journal\": \"Journal of cellular physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — luciferase reporter + KD experiments + in vivo, single lab\",\n      \"pmids\": [\"30230527\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"DNMT1 hypermethylates the miR-124-3p promoter to silence miR-124-3p; miR-124-3p directly targets the BCAT1 mRNA 3'-UTR to suppress BCAT1 expression; DNMT1 knockdown reduces BCAT1 via miR-124-3p restoration in esophageal squamous cell carcinoma.\",\n      \"method\": \"miR-124-3p 3'-UTR targeting of BCAT1 (luciferase assay inferred); DNMT1 knockdown; miR-124-3p overexpression reducing BCAT1; proliferation/migration assays\",\n      \"journal\": \"BMC cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — mechanistic axis established by KD experiments, single lab\",\n      \"pmids\": [\"31226958\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"BCAT1 promotes TNBC progression by maintaining leucine, isoleucine, and valine (BCAA) synthesis; BCAA-supported SHOC2 (a leucine-rich repeat protein) expression activates downstream RAS-ERK signaling; Eupalinolide B (EB) was identified as a direct BCAT1 inhibitor and inhibits SHOC2-RAS-ERK to induce TNBC cell apoptosis.\",\n      \"method\": \"ABPP technology + pull-down WB + CETSA-WB + MST identifying BCAT1 as direct EB target; HPLC metabolomics; proteomic sequencing; BCAT1 KO/OE with SHOC2-RAS-ERK pathway readout; in vivo mouse models\",\n      \"journal\": \"Journal of advanced research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple direct target identification methods (ABPP, CETSA, MST) + pathway validation + in vivo\",\n      \"pmids\": [\"39490614\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"HuR RNA-binding protein directly binds BCAT1 mRNA and increases its stability and translation, thereby upregulating BCAT1 protein levels; elevated BCAT1 activates ERK5 signaling to promote castration-resistant prostate cancer progression.\",\n      \"method\": \"RNA immunoprecipitation (RIP) assay; mRNA half-life assay; HuR KO by Cas9; HuR inhibitor KH-3; ERK5 pathway measurement\",\n      \"journal\": \"Journal of translational medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — RIP + mRNA stability assay + genetic KO + pharmacological inhibition, single lab\",\n      \"pmids\": [\"38369471\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"In AML cells, high BCAT1 expression limits intracellular αKG levels, which impairs αKG-dependent histone demethylase activity and upregulates H3K9me3; elevated H3K9me3 inhibits ATM expression and blocks DNA damage repair, sensitizing high-BCAT1 AML cells to PARP inhibitors.\",\n      \"method\": \"BCAT1 KO/OE AML cell lines; αKG measurement; H3K9me3 ChIP; ATM expression; PARP inhibitor sensitivity in vitro and in vivo\",\n      \"journal\": \"Journal of molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — KO/OE + αKG/histone methylation measurements + functional DNA repair readout, single lab\",\n      \"pmids\": [\"38340163\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"BCAT1 promotes leukemia development downstream of the P2X1-PBX3 signaling axis; ATP-P2X1 signaling upregulates PBX3 which transactivates BCAT1, and BCAT1 is required to maintain leukemia-initiating cell self-renewal.\",\n      \"method\": \"P2X1 deletion mouse AML model; PBX3-BCAT1 transactivation; BCAT1 knockdown in human AML cell lines; in vivo transplantation assays\",\n      \"journal\": \"Leukemia\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — genetic pathway epistasis in mouse model + human cell lines, single lab\",\n      \"pmids\": [\"36418376\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"BCAA/BCAT1 signaling enhances CREB phosphorylation, which is required for maintenance of TKI-resistant CML cells; BCAT1 knockdown dramatically reduces proliferation of TKI-resistant human leukemia lines and abrogates leukemia in BCR-ABL-T315I murine CML model.\",\n      \"method\": \"BCAT1 knockdown in murine BCR-ABLT315I CML model + human TKI-resistant cell lines; BCAA stimulation; CREB phosphorylation measurement; in vivo transplantation\",\n      \"journal\": \"Cellular oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic KD + pathway readout + in vivo, single lab\",\n      \"pmids\": [\"39412615\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"BCAT1 activation in Müller cells under diabetic conditions reduces intracellular αKG, increases H3K4me3 at inflammatory gene (IL-6, TNF-α) promoters, and drives retinal inflammation; Plk4 kinase phosphorylates BCAT1 at threonine 333 to negatively regulate its activity.\",\n      \"method\": \"ChIP for H3K4me3 at inflammatory gene promoters; targeted metabolomics (αKG measurement); kinase screening identifying Plk4; BCAT1 inhibitor (BAY-069, ERG240) treatment in diabetic mouse models; Bcat1 single-cell expression mapping\",\n      \"journal\": \"Investigative ophthalmology & visual science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP + metabolomics + kinase identification + in vivo validation, single lab\",\n      \"pmids\": [\"40530920\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Transcription factor EB (TFEB) transcriptionally regulates BCAT1 expression; TFEB knockdown inhibits BCAA catabolism in pancreatic cancer cells by blocking BCAT1, reducing cell proliferation and metastasis.\",\n      \"method\": \"TFEB knockdown; BCAT1 expression measurement; BCAA catabolism assays; proliferation and metastasis assays; BCAA deprivation + eltrombopag (TFEB inhibitor) combination\",\n      \"journal\": \"Cell proliferation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — transcription factor KD with BCAT1 as downstream target, single lab\",\n      \"pmids\": [\"38938061\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"NR4A1 nuclear receptor transcriptionally inhibits Bcat1 expression in macrophages; NR4A1 deficiency upregulates Bcat1, which activates the integrated stress response (ISR) in macrophages, promoting vulnerable atherosclerotic plaque formation.\",\n      \"method\": \"NR4A1 KO mouse (ApoE-/-;NR4A1-/-) vulnerable plaque model; Bcat1 identified as NR4A1 transcriptional target; Bcat1 inhibitor (ERG240) treatment; ISR pathway measurement\",\n      \"journal\": \"Cellular and molecular life sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO model + pharmacological inhibition + transcriptional target identification, single lab\",\n      \"pmids\": [\"39985585\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"BCAT1 inhibition in trophoblasts blocks NF-κB pathway activation (reducing p-IκBα and nuclear NF-κB p65 translocation), suppresses NLRP3 inflammasome activation, reduces inflammatory cytokine release, and decreases trophoblast apoptosis in LPS-induced inflammation models.\",\n      \"method\": \"BCATc Inhibitor 2 treatment; EMSA for NF-κB DNA binding; p-IκBα and nuclear NF-κB p65 immunoblot/IF; TUNEL apoptosis assay; cytokine ELISA; LPS-induced mouse pregnancy loss model\",\n      \"journal\": \"Cell and tissue research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — pharmacological inhibition + multiple pathway readouts + in vivo model, single lab\",\n      \"pmids\": [\"39356334\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"BCAT1 controls embryonic neural stem cell (NSC) proliferation and differentiation; BCAT1 is specifically highly expressed in layer II/III and IV neurons, and shRNA-mediated BCAT1 suppression reduces NSC proliferation and causes abnormal development of these cortical layers.\",\n      \"method\": \"Single-cell RNA-seq trajectory analysis; shRNA knockdown of BCAT1 in NSCs; assessment of cortical layer neuron development in vivo\",\n      \"journal\": \"Molecular brain\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — scRNA-seq + in vivo shRNA KD with defined developmental phenotype, single lab\",\n      \"pmids\": [\"37344908\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"BCAT1 activity is required for ferroptosis protection in myocardial ischemia; BCAT1/BCAT2 overexpression activates the Keap1/Nrf2/HO-1 antioxidant pathway, and BCAT1 or BCAT2 siRNA knockdown promotes ferroptosis and decreases cell viability in cardiomyocytes.\",\n      \"method\": \"BCAT1/BCAT2 siRNA knockdown; cardiac-specific BCAT1/BCAT2 overexpression in MI mice; Keap1/Nrf2/HO-1 pathway measurement; ferroptosis markers (GPX4, ACSL4); metabolomics identifying BCAT1/BCAT2 as RUS targets\",\n      \"journal\": \"Antioxidants (Basel, Switzerland)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — KD + OE + pathway readout + in vivo, single lab\",\n      \"pmids\": [\"35326233\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"BCAT1 expression is regulated by STAT3: mutant IDH1 inhibitor treatment decreases mutant IDH1-STAT3 binding, freeing STAT3 for phosphorylation at Tyr-705 (pSTAT3-Y705) and nuclear translocation, which transcriptionally increases BCAT1 levels; STAT3 knockdown or inhibition attenuates mutant IDH1 inhibitor-mediated BCAT1 upregulation.\",\n      \"method\": \"STAT3 knockdown; pharmacological STAT3 inhibition; pSTAT3-Y705 immunoblot; nuclear translocation assay; Co-immunoprecipitation of mutant IDH1-STAT3; BCAT1 expression measurement\",\n      \"journal\": \"Biochimica et biophysica acta. Molecular cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — Co-IP + KD + nuclear translocation, single lab with multiple methods\",\n      \"pmids\": [\"34329662\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"BCAT1 (cytosolic branched-chain amino acid transaminase 1) catalyzes the reversible transamination of branched-chain amino acids (leucine, isoleucine, valine) with α-ketoglutarate (αKG) to produce glutamate and branched-chain α-keto acids (BCKAs); by consuming αKG it limits TET2/dioxygenase activity and DNA demethylation, while its BCKA products directly activate RhoC GTPase and sustain mTORC1 signaling to drive cell proliferation; additionally, BCAT1 harbors a CXXC redox motif that localizes to mitotic structures to regulate Aurora B kinase centromere localization and ensure faithful chromosome segregation, and its expression is transcriptionally controlled by c-Myc, NOTCH1, STAT3, NR4A1, and TFEB, while its protein stability is regulated by BCKDK-mediated phosphorylation and CHIP/STUB1-mediated ubiquitin-proteasome degradation (counteracted by SIRT5 desuccinylation).\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"BCAT1 is the cytosolic branched-chain amino acid transaminase that reversibly transfers α-amino groups from leucine, isoleucine, and valine to α-ketoglutarate, generating glutamate and branched-chain α-keto acids (BCKAs), thereby coupling BCAA catabolism to α-KG availability, mTORC1 signaling, and epigenetic regulation. By consuming α-KG, BCAT1 restricts the activity of α-KG-dependent dioxygenases including TET2 and histone demethylases, driving DNA and histone hypermethylation that phenocopies IDH mutations in AML and glioma [PMID:29144447, PMID:38340163]; its BCKA products directly activate RhoC GTPase to promote cell motility [PMID:37337119] and sustain oxidative phosphorylation and nucleotide biosynthesis required for proliferation [PMID:35499760]. Independent of its transaminase activity, BCAT1 possesses a CXXC redox motif that confers antioxidant H₂O₂-metabolizing capacity and localizes to mitotic structures to regulate Aurora B kinase centromere targeting, ensuring accurate chromosome segregation [PMID:36260995, PMID:35453368]. BCAT1 protein stability is controlled by BCKDK-mediated phosphorylation that antagonizes STUB1/CHIP E3 ubiquitin ligase-dependent K48-linked ubiquitination and proteasomal degradation, a process counteracted by SIRT5 desuccinylation at K39 [PMID:38621458, PMID:39075053, PMID:40195331].\",\n  \"teleology\": [\n    {\n      \"year\": 1999,\n      \"claim\": \"The earliest functional evidence showed that BCAT1 enzymatic products — specifically the branched-chain keto acid α-ketoisocaproate — have direct biological activity, capable of inducing apoptosis, establishing that BCAT1's downstream metabolites are not inert intermediates.\",\n      \"evidence\": \"BCAT1 overexpression and α-ketoisocaproate supplementation in murine cells under serum deprivation\",\n      \"pmids\": [\"10471790\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab, not independently replicated\", \"Mechanism of BCKA-induced apoptosis not defined\", \"Physiological relevance of overexpression-level metabolite flux unclear\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"BCAT1 was found to be neuron-specific in the adult brain with differential subcellular localization in glutamatergic versus GABAergic neurons, suggesting a role in neurotransmitter precursor supply.\",\n      \"evidence\": \"Immunohistochemistry in rat brain with cell-type resolution\",\n      \"pmids\": [\"15329886\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Descriptive localization only; no functional perturbation in neurons\", \"Whether BCAT1 controls neurotransmitter pools was not tested\", \"Human relevance not demonstrated\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Two studies established BCAT1 as both a critical metabolic dependency in glioblastoma (through glutamate production and proliferation support) and a direct transcriptional target of c-Myc, linking oncogene activation to BCAA catabolism.\",\n      \"evidence\": \"shRNA knockdown in glioma cells with xenograft validation; ChIP and luciferase reporter assays for c-Myc binding to BCAT1 promoter in nasopharyngeal carcinoma\",\n      \"pmids\": [\"23793099\", \"23758864\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether c-Myc regulation of BCAT1 is universal across cancer types\", \"Identity of downstream metabolic effectors beyond glutamate not resolved\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Using knockout mice, BCAT1 was shown to control intracellular leucine levels in CD4+ T cells downstream of TCR/calcineurin-NFAT signaling, with BCAT1 loss causing aberrantly elevated mTORC1 activity, revealing BCAT1 as a metabolic rheostat for immune cell activation.\",\n      \"evidence\": \"BCATc knockout mouse T cells; mTORC1 substrate phosphorylation; glycolysis measurement\",\n      \"pmids\": [\"24847056\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether BCAT1's mTORC1-modulating role is mediated by leucine depletion versus BCKA production\", \"Effects on T cell differentiation and in vivo immune responses not fully characterized\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"A pivotal mechanistic advance showed that BCAT1 controls α-KG availability in AML, directly linking its transaminase activity to epigenetic reprogramming: BCAT1 overexpression depleted α-KG, impaired TET2 dioxygenase activity, and caused DNA hypermethylation phenocopying IDH mutations.\",\n      \"evidence\": \"BCAT1 knockdown/overexpression in AML cells with metabolomics, DNA methylation profiling, and HIF1α degradation measurement\",\n      \"pmids\": [\"29144447\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether BCAT1's epigenetic effects are sufficient for leukemic transformation alone\", \"Relative contributions of TET2 versus EGLN1/HIF1α pathways downstream of α-KG depletion\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"The metabolic crosstalk axis was expanded to the tumor microenvironment when BCAT1 in cancer-associated fibroblasts was shown to be regulated by TGF-β/SMAD5 signaling, producing BCKAs that are secreted to fuel pancreatic cancer cell metabolism.\",\n      \"evidence\": \"TGF-β/SMAD5 manipulation in CAFs; isotope tracing of BCAA metabolism; patient-derived material validation\",\n      \"pmids\": [\"32694827\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether BCKA transfer from CAFs to cancer cells involves specific transporters\", \"Quantitative contribution of CAF-derived BCKAs versus cancer cell-autonomous BCAA catabolism\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"A non-metabolic moonlighting function was discovered: BCAT1 localizes to mitotic structures and its CXXC redox motif controls Aurora B kinase centromere localization and chromosome segregation accuracy, independent of its transaminase activity. Separately, the CXXC motif was shown to directly metabolize H₂O₂, conferring intrinsic antioxidant activity.\",\n      \"evidence\": \"CXXC motif mutagenesis with rescue in cancer cells and iPSCs; purified recombinant BCAT1 H₂O₂ metabolism assay; live-cell imaging and chromosome segregation assays\",\n      \"pmids\": [\"36260995\", \"35453368\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis for how CXXC sulfenylation recruits Aurora B\", \"Whether the antioxidant function and mitotic function are mechanistically coupled\", \"Relative contribution of redox versus metabolic functions to tumor growth\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"BCKA products of BCAT1 were established as the critical downstream effectors in GBM, rescuing oxidative phosphorylation, mTORC1 activity, and nucleotide biosynthesis after BCAT1 loss, resolving the question of whether α-KG depletion or BCKA generation is the dominant output.\",\n      \"evidence\": \"BCAT1 KO with BCKA supplementation rescue in patient-derived GBM models; metabolic measurements including NAD+/NADH and nucleotides\",\n      \"pmids\": [\"35499760\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular targets of BCKAs that restore mTORC1 and nucleotide synthesis\", \"Whether BCKAs act through allosteric effects, as metabolic fuels, or as signaling molecules\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"The signaling mechanism of BCAT1-derived BCKAs was partly resolved: BCAT1 directly interacts with RhoC GTPase, and BCKAs bind RhoC to activate its GTPase activity, providing a direct metabolite-to-signaling link driving cell motility and metastasis.\",\n      \"evidence\": \"Co-IP of BCAT1-RhoC; biochemical BCKA-RhoC binding assay; gain-of-function BCAT1-E61A mutant; in vivo metastasis model\",\n      \"pmids\": [\"37337119\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of BCKA-RhoC binding\", \"Whether BCKA-RhoC activation occurs in non-cancer contexts\", \"Specificity for RhoC versus other Rho family GTPases\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"The post-translational regulation of BCAT1 was delineated: BCKDK phosphorylates BCAT1 at S5/S9/T312 to enhance activity and stability; STUB1/CHIP ubiquitinates BCAT1 at K48/K360 for proteasomal degradation; and BCKDK also phosphorylates STUB1-S19 to disrupt its interaction with BCAT1, creating a coherent stabilization circuit.\",\n      \"evidence\": \"Mass spectrometry phosphosite mapping; Co-IP; ubiquitination and in vitro kinase assays; domain mapping of CHIP-BCAT1 interaction; glioma models\",\n      \"pmids\": [\"38621458\", \"39075053\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Phosphatases that reverse BCKDK-mediated phosphorylation\", \"Whether BCKDK regulation of BCAT1 is tissue-specific\", \"Crystal structure of BCAT1-CHIP complex\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"SIRT5 was identified as a desuccinylase stabilizing BCAT1 by removing succinylation at K39, which otherwise promotes CHIP-mediated ubiquitination; separately, NOTCH1 and NR4A1 were identified as direct transcriptional regulators of BCAT1 in T-ALL and macrophages respectively, expanding the transcription factor repertoire controlling BCAT1.\",\n      \"evidence\": \"SIRT5-BCAT1 interaction by proteomics and Co-IP with succinylation site mapping; NOTCH1 ChIP at BCAT1 promoter with genetic KO; NR4A1 KO mouse atherosclerosis model\",\n      \"pmids\": [\"40195331\", \"39234857\", \"39985585\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Succinylation writer enzyme for BCAT1-K39 unknown\", \"Whether SIRT5-BCAT1 axis operates beyond glioma\", \"Full promoter architecture integrating c-Myc, NOTCH1, STAT3, NR4A1, TFEB inputs\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include: the structural basis for BCAT1's CXXC-mediated mitotic and antioxidant functions, how BCKA metabolites allosterically activate diverse targets (RhoC, mTORC1), whether the metabolic and redox moonlighting functions are coordinately regulated in vivo, and the physiological significance of BCAT1 in neuronal BCAA metabolism and neurotransmitter production.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No crystal structure of BCAT1 in complex with mitotic or signaling partners\", \"No reconstituted system demonstrating BCKA direct activation of mTORC1\", \"Neuron-specific BCAT1 knockout phenotype not reported\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [0, 2, 3, 10, 13]},\n      {\"term_id\": \"GO:0016209\", \"supporting_discovery_ids\": [9, 8]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [11, 8]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [0, 2, 3]},\n      {\"term_id\": \"GO:0005694\", \"supporting_discovery_ids\": [8]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [0, 2, 3, 10, 7]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [3, 6, 11, 24]},\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [2, 26]},\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [8]},\n      {\"term_id\": \"R-HSA-9612973\", \"supporting_discovery_ids\": [12, 19]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [14, 15, 16]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"STUB1\",\n      \"BCKDK\",\n      \"SIRT5\",\n      \"RHOC\",\n      \"IRE1\",\n      \"AURB\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}